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Abstract  
 
Single nucleotide polymorphisms in the gene for the cytokine, interleukin-22, have 
been associated with severe malaria infection. This cytokine is known to have roles 
in protecting various tissues from the damaging effects of inflammation as well as by 
up-regulating the production of antimicrobial peptides. This thesis aims to investigate 
where IL-22 is produced in the mouse model of malaria infection, Plasmodium 
chabaudi in C57BL/6 mice, and whether this production provides protection from 
associated pathology.  
  
IL-22 expression was analysed through qRT-PCR and the use of an IL-22 cre x R26R 
eYFP fate reporter mouse. In the liver, there were increases in mRNA until day 5, 
when they decreased, and a similar pattern was observed in eYFP+ cells. In the lungs, 
there was also a decrease in il22 mRNA as well as eYFP+ cells after day 5 and this was 
shown to result from changes in the population of IL-22 producing γδ T cells. 
Decreases were observed in il22 mRNA in the small intestine with no change in eYFP+ 
cells in the small or large intestine. These eYFP+ cells were mostly comprised of innate 
lymphoid cells and a possibility may have been that a proportion of them had 
switched to producing IFN-γ due to increased IL-12 expression in malaria infection.  
 
C57BL/6 mice deficient in IL-22 (il22-/- mice) that were infected with P. c. chabaudi AS 
and P. c. chabaudi CB showed a decreased survival with increases in the liver 
enzymes. However changes in histopathology were not observed in the lungs, liver 
and intestine in the absence of IL-22 in malaria infection, suggesting the role of this 
cytokine may be subtle. Future work would need to further investigate whether the 
importance of IL-22 in malaria infection is due to its roles in protecting the integrity 
of the epithelia especially within the intestine and lung or its influences on the 
intestine microbiota.  
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1. Introduction 
1.1 The impact of malaria   
Transmitted by mosquitoes of the Anopheles genus and caused by the intracellular 
apicomplexan parasite Plasmodium, malaria threatens approximately 3.3 billion of 
the world’s population. In 2013, there were an estimated 207 million cases of this 
disease globally leading to around 600,000 deaths most of which were in children 
under the age of 5 (1-3).  The economic burden of this disease is also estimated to be 
significant, with gross domestic product (GDP) known to be reduced in malaria 
endemic countries (4).  
 Over 100 species of Plasmodium are known to exist, infecting many 
vertebrate hosts such as birds, reptiles and mammals (3). Five of these species are 
able to cause pathology in humans. These include Plasmodium vivax, P. malariae and 
P. ovale, as well as P. knowlesi, a malaria parasite known to infect primates such as 
macaques which has more recently been shown to affect humans as well. Of the 
malaria parasites that infect humans, P. falciparum is known to cause the most 
deaths and severe complications observed in this disease (5). 
 
1.2 The life cycle of Plasmodium in mammals 
Once bitten by a Plasmodium-infected mosquito, sporozoites residing within the 
salivary glands are transmitted into the dermis of the host's skin, as the mosquito 
probes for a blood vessel (6). As shown in figure 1.1, these parasites then move into 
the bloodstream where they travel to the liver and infect hepatocytes (7). The liver 
stage of malaria is asymptomatic and lasts until the sporozoites produce thousands 
of merozoites within the hepatocyte. In Plasmodium ovale and Plasmodium vivax, 
the parasite may also form into hypnozoites, which remain dormant in the liver of 
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the host for months to years and resurface causing pathology in a future relapse (3, 
8-10). 
 The merozoites occupy vesicles called merosomes within the hepatocytes, 
which pass into the bloodstream (12) . In the erythrocytic stage of disease, 
merozoites then invade erythrocytes, dividing asexually within them progressively 
through rings, trophozoite and 
multinucleate schizonts stages, 
and then egressing to invade more 
erythrocytes. This egress is known 
to require activity of proteases 
(13). Some species of Plasmodium 
(P) such as P. vivax, preferentially 
invade reticulocytes where as 
others such as P. falciparum invade 
erythrocytes at all stages of development (3, 5, 14). 
 The rupture of infected erythrocytes in the erythrocytic stage cycle of division 
and egress is associated with the symptomatic stage of malaria, and symptoms can 
include fever, headaches and vomiting in humans (15).  
 After invasion of the red blood cell, some merozoites develop into male and 
female gametocytes, this fate has been linked to expression levels of the DNA binding 
protein PfAP2-G within the parasites (16). Mature gametocytes circulate within the 
blood, enabling them to be taken into the mosquito on a subsequent bite of the host. 
Within the mosquito, gametocytes fuse to form oocysts in the mid-gut, which release 
sporozoites that travel to the salivary glands thus continuing the cycle. 
   
Figure 1.1 from Perez-Mazliah & Langhorne (11) shows 
the life cycle of the malaria parasite, Plasmodium, 
which occurs in two main stages the pre-erythrocytic 
or liver-stage and the erythrocytic or blood stage of 
infection. 
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1.3 Pathological complications in malaria   
The symptoms of pathology in malaria arise during the erythrocytic stage of infection. 
In humans, this begins within 6 to 8 days after being bitten by a mosquito. (2,5). In P. 
falciparum infection, these symptoms occur with defined periodicity; coinciding with 
the rupture of the schizont-infected erythrocytes. In most infections these symptoms 
resolve with treatment. However, in approximately 10% of infections with P. 
falciparum, complications can arise during malaria infection leading to severe 
symptoms of this disease, in which organs such as the brain, lungs, liver as well as the 
placenta in pregnant women can be affected (17, 18). 
 Severe symptoms may arise from a feature of P. falciparum infection known 
as sequestration in which infected erythrocytes adhere to vascular endothelium 
enabling the parasite to avoid destruction by the spleen (2,6). P. falciparum expresses 
the protein, P. falciparum erythrocyte membrane protein 1 (PfEMP1), on the surface 
membrane of the infected erythrocyte. This protein, encoded by the var multigene 
family (19), is able to bind receptors on the host endothelium such as CD36, 
chondroitin sulphate A (CSA) and ICAM-1 (5).  
 Cerebral malaria, the most serious complication that can result from malaria 
infection, can lead to coma, lifelong disability, or even death. The exact mechanisms 
of pathogenesis in cerebral malaria remain under debate (20, 21). Some argue that 
sequestration of the malaria parasite within blood vessels of the brain contributes to 
this syndrome since sequestered parasites can be observed in histological sections of 
organs of malarial patients who died of cerebral malaria. However, this is still 
observed in patients who die of malaria complications other than cerebral malaria, 
albeit to a lesser degree (22). Evidence also points to proinflammatory cytokines 
 10 
inducing this complication, with Tumour Necrosis Factor (TNF) reported to play a role 
(23, 24) .   
  Severe anaemia is another serious complication of this disease that can result 
from the destruction of infected erythrocytes by the immune system as well as 
haemolysis and the suppression of erythrocyte development by proinflammatory 
cytokines (25-27). It can also be caused by the increased destruction of uninfected 
erythrocytes (28). 
 Pregnant women infected with malaria are at an increased risk of 
miscarriages, low birth weight and severe disease as a result of placental malaria. 
Here, malaria parasites are able to bind to factors such as chondroitin sulfate A (CSA) 
allowing them to sequester within the placenta (15).  
 Lung pathology can also arise in malaria associated acute respiratory distress 
syndrome (MA-ARDS) in which inflammatory cells and mediators infiltrate the lung 
tissues (29-31). In studies using mouse models, this has been also associated with 
parasite sequestration and may also present with proteins in the broncheoalveolar 
lavage during malaria infection, signalling a decreased integrity of the lung epithelia 
(29, 32). This syndrome differs from metabolic acidosis, another complication of 
malaria, which occurs when the tissues starved of oxygen because of sequestered 
parasites in blood vessels undergo anaerobic respiration (33). Malaria infections have 
also been known to cause acute renal failure (34) as well as acute liver failure (35).  
 Secondary bacterial coinfections and increased endotoxaemia have also been 
associated with severe malaria infections, with non-typhoidal salmonella being the 
most commonly reported (36-38). Studies have found that this bacteraemia can triple 
the risk of mortality (39). Malaria infection has been shown to prime the 
inflammatory response to bacterial products such as lipopolysaccharides resulting in 
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exaggerated production of the cytokine IL-1β leading to dangerously high levels of 
inflammatory responses (40, 41).  
 Increased endotoxaemia and bacterial coinfection in malaria have been 
suggested to stem from perturbations to epithelial barriers in the gastrointestinal 
tract allowing translocation of bacteria (42). The involvement of the gastrointestinal 
tract has been suggested in studies examining this organ in mouse models of malaria 
infection. Using P. yoelii infection, Chau et al.  (43) have suggested a mechanism in 
which reduction of nitric oxide in the intestine, due to its increased use to kill malaria 
parasites, could activate the degranulation of mast cells. These cells would then 
damage the integrity of the epithelial tight junctions and allow the dissemination of 
bacteria such as Salmonella typhimurium. Mooney et al.  (44) propose that increased 
production of the anti-inflammatory cytokine IL-10 during malaria infection in the 
intestine could lead to blunting of inflammatory responses to bacteria, allowing their 
dissemination.  
 
1.4 Mouse models of malaria infection 
There are many questions that need to be answered in order to minimise the burden 
of this disease. These include the nature of immune responses that are generated 
against the parasite during infection, how these immune responses can lead to 
development of immunological memory and whether a vaccine can be used to induce 
this. How exactly severe pathology ensues, and how the parasite can be potentially 
pharmacologically inhibited. An invaluable way of answering these questions is by 
using mouse models of malaria infection. 
 Infecting inbred strains of laboratory mice such as BALB/c and C57BL/6 with 
rodent-specific species of the parasite Plasmodium has proven to provide an 
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invaluable opportunity to decipher the complex interactions that occur between the 
parasite and its host during malaria infection (42, 45). Through generating mice 
deficient in genes such as those for immune mediators and cytokines, it is also 
possible to elucidate the role of these factors through observing alterations in 
pathology (2, 3, 46, 47). 
 Most mouse models of malaria infection have been developed using parasites 
isolated from African thicket rats (e.g. Grammomy rutilans and Grammomys 
surdaster) these include P. berghei, P. yoelii, P. c. chabaudi, P. c. adami and P. vinckei 
(48). These different species and subspecies vary in their characteristics such as 
virulence, synchronicity and pathological complications. Even within a species such 
as P. c. chabaudi there are subspecies and strains of differing virulence (47, 48). The 
ability to also manipulate the genome of P. berghei, P. yoelii and P. c. chabaudi to tag, 
knockout and knock-in genes gives opportunities to investigate processes in vivo such 
as sequestration and invasion, which would not be possible in humans (49-53).   
1.4 Plasmodium chabaudi chabaudi  
Plasmodium chabaudi chabaudi is a useful model of malaria infection because of the 
similarities it shares with some of the human infecting malaria parasites, including P. 
falciparum. Like this debilitating human infecting parasite, P. c. chabaudi is also able 
to establish a chronic and synchronous infection and also undergoes sequestration 
(54). The severity of malaria infection in the mouse can depend upon the strain of P. 
c. chabaudi as well as the strain of mouse. The strains, P. c. chabaudi chabaudi AS 
and P. c. chabaudi adami cause infections which are usually eliminated by inbred 
mouse strains such as C57BL/6 but have a high mortality rate in other strains such as 
A/J (48). 
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 P. c. chabaudi chabaudi AS in C57BL/6 mice establishes a non-lethal but 
chronic infection with sequestration, although, unlike P. falciparum this occurs in the 
liver and lungs but not in the brain (32). As this infection is non-lethal and chronic, 
the immune responses of the host, which can clear the parasite, can be studied in 
depth. Genetic engineering of this parasite is also possible, allowing P. c. chabaudi to 
be transformed to express fluorescent proteins such as mCherry (50). Through in-vivo 
imaging of infected mice, processes such as sequestration in the host can be analysed 
in further detail (32). More virulent strains of P. c. chabaudi exist such as P. c. 
chabaudi chabaudi CB, which can cause a higher rate of mortality in infected C57BL/6 
mice.  
 Mice are usually injected intraperitoneally with 10,000 serially blood-
passaged infected erythrocytes. Analysis of parasitaemia typically reveals a peak at 
around days 7 to 9, which is associated with weight loss, anaemia and hypothermia. 
This stage of the infection is associated with a Th1 response induced by IL-12 
involving the proinflammatory cytokines IFN-γ and TNF-α, which can activate 
macrophages to destroy the parasites (55-58). After this peak, antibody responses 
are important for maintaining the clearance of parasites. In the chronic stage, 
recrudescence of parasites can also appear which may be associated with antigenic 
variation (59, 60).  
 Brugat et al.  (32) have shown that organs in which mature P. c. chabaudi 
sequester, can develop pathology. In the lung, sequestration was linked to the 
production of IFN-γ, which accompanies the acute stage of this infection (32). 
Damage was also observed to the epithelium indicated by increased proteins in the 
broncheoalveolar lavage fluid. Alveolar septae cellularity, a histopathological 
measure of influx of inflammatory cells, was also observed to increase here.   
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 Sequestration of P. c. chabaudi in C57BL/6 was associated with signs of tissue 
damage as shown by histopathology and by detection of liver enzymes in the plasma, 
such as alanine transaminase (ALT) (32). Seixas et al.  (61) showed a TNF dependent 
mechanism for liver damage in P. c. chabaudi infection in BALB/c mice. Haemozoin is 
a pigment released by malaria parasites as a result of breakdown of haemoglobin and 
it may induce the release of proinflammatory cytokines(62). Brain pathology has not 
been observed in P. c. chabaudi AS infection, although, il10-/- mice have been shown 
to develop some breakdown of the blood brain barrier and some neurological 
symptoms during infection (63).   
 Since infection initiated via intraperitoneal injection of infected erythrocytes 
is different from the natural mode of transmission of malaria, a protocol has been 
optimised in which P. c. chabaudi can be successfully transmitted to mice via the bite 
of the mosquito, Anopheles stephensi (64). It has been found that after mosquito 
transmission, there is a lower peak of parasitaemia, with reduced virulence (65). This 
has been observed to be associated with changes in gene expression of the cir 
multigene family (66). 
 
1.6 Immune responses to the liver-stage of Plasmodium 
Although the stages of Plasmodium infection in which sporozoites infect hepatocytes 
within the liver are clinically silent, the host is still able to raise immune responses in 
efforts to clear the parasite. Injection of sporozoites attenuated by radiation leads to 
protective immunity in mice and humans (66, 68).  In vitro experiments have shown 
that antibodies against Plasmodium berghei sporozoites can block invasion of 
hepatocytes (69). Studies in mice by Schofield et al.  (70) showed that as well as 
antibodies against sporozoites attenuated by radiation, important immune 
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responses at this stage also included the release of interferon-gamma and CD8+ T 
cells. These cells have been shown through in vivo imaging of the infected mouse 
liver to form clusters around infected hepatocytes to eliminate them, in mice that 
were pre-immunized by previous infection with radiation attenuated sporozoites 
(71). Work by Hill et al.  (72) which showed the major histocompatibility complex 
(MHC) class I allele, HLA B53 that is recognised by CD8+ T cells is associated with 
resistance to severe malaria, strongly suggesting that this CD8+ T cell response is also 
important in humans.  
  In addition to adaptive immunity mediated by antibodies and T cells, studies 
by Liehl et al.  (73) demonstrated in P. berghei infected mice that there is also a 
hepatocyte intrinsic innate response where infection of these cells with sporozoites 
leads to their secretion of type 1 interferon. This cytokine may then act in an 
autocrine manner, inducing the hepatocytes to initiate transcription of interferon-
stimulated genes (ISGs), which include chemokines, attracting innate immune cells 
that can kill infected hepatocytes.  
 
1.7 Immune responses to the erythrocytic-stage of Plasmodium 
Innate immune responses towards the erythrocytic stage of Plasmodium can be 
initiated by the activation of receptors on cells of the innate immune system such as 
macrophages and dendritic cells by Pathogen-Associated Molecular Patterns 
(PAMPS). Plasmodium PAMPS include substances such as haemozoin, a breakdown 
product of haem which can activate inflammatory pathways through NLRP3 resulting 
in the production of proinflammatory cytokine, interleukin-1β (IL-1β) (49, 51). 
Glycosylphosphatidylinositol (GPI) from P. falciparum has also been shown to 
activate TLR2 leading to inflammatory pathways through Myd88 (2, 3, 74, 75). These 
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signalling pathways may lead to the activation of the transcription factor, NF-κB 
which can induce production of inflammatory cytokines (3, 47, 76).   
 Through activation of these pathways, dendritic cells and macrophages can 
secrete cytokines such as TNF-α, IL-6, IL-12 and IL-18 which can go on to activate 
natural killer (NK) cells to secrete cytokines such as IFN-γ and TNF-α this has been 
shown in studies in mice and humans (5, 77). Human NK cells have also been shown 
in vitro to secrete IFN-γ rapidly in response to live P. falciparum infected erythrocytes 
(78). Studies have shown that P. c. chabaudi infected mice in which NK cells are 
depleted have a significantly higher parasitaemia and a 100% mortality (79) 
demonstrating the importance of these cells in control of parasites. 
 Activated antigen presenting cells (APCs) such as dendritic cells, take up, 
process and present peptides within major histocompatibility complex (MHC) class II 
proteins to CD4+ T cells. These cells then undergo cell division and differentiate into 
T cells which can act as effector cells through their production of cytokines or which 
develop into helper cells for B cells produce antibodies, resulting in the adaptive 
immune response (3, 5, 14, 80).  CD4+ T cells, in particular, are able to differentiate, 
through the expression of master regulator transcription factors and induce various 
T helper (Th) responses in infection, depending on the cytokine milieu (81). These 
include Th1 cells, which express the master regulator T-bet, and the cytokine IFN-γ.  
Th2 cells which express GATA-3 and secrete IL-4. Th17 cells which express RORγT and 
express IL-17 and IL-22. They can also differentiate into follicular helper T cells (Tfh 
cells), which express IL-21 or induced Regulatory T cells (Tregs) that possess the 
master regulator FOXP3 and express the cytokine TGF-β (81-83).  
 IL-12 from antigen-presenting cells can induce a Type 1 helper response (Th1) 
in CD4+ T cells stimulating them to secrete IFN-γ. (2, 3, 76, 84). In-vitro experiments 
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by Pombo et al.  (85)have shown large amounts of nitric oxide synthase activity during 
erythrocytic stage infection in humans, suggesting that nitric oxide induced by IFN-γ 
may be important for killing the malaria parasite.  However, studies in mice have 
shown that nitric oxide is dispensable for controlling malaria infection (21, 86, 87).  
 Antibodies, produced by plasma cells, are known to have an important role in 
parasite clearance in the chronic phase of infection. Earlier studies have shown that 
passive transfer of antibodies from hyperimmune adult humans can result in reduced 
parasitaemia (88). Other studies have also shown an association between antibodies 
against the malaria parasite and protection or a reduced incidence of malaria 
infection in humans (89, 90).  
 Mice deficient in IL-4, an important Th2 cytokine are known to still mediate 
appropriate antibodies against P. c. chabaudi showing that this cytokine does not 
have an important role in the protective immune response to this parasite (59). 
Recently published studies by Pérez-Mazliah et al.  (91) have revealed that 
interleukin-21, produced by CD4+ follicular T helper (Tfh) cells, are more important 
in orchestrating the B-cell response in germinal centres to control the chronic phase 
of P. c. chabaudi in C57BL/6 mice. 
 Despite immune responses raised against the malaria parasite, humans 
acquire long lasting protective immunity only after several years of exposure and 
never acquire sterile protection (47). This has been suggested to be due to immune 
evasion through antigenic variation in Plasmodium (32, 92). Antigens such as PfEMP1 
that are expressed on the surface of infected erythrocytes are known as variant 
surface antigens (VSAs) and are encoded by P falciparum multigene families such as 
the var gene family encoding PfEMP1 in P. falciparum. The parasite can induce 
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expression of variants of these proteins to avoid recognition by the immune system 
whilst still allowing them to function (25-27, 93, 94).  
 The Plasmodium interspersed repeat (pir) multigene family has also been 
found in all species of Plasmodium so far sequenced such as P. vivax (vir), P. yoelii 
(yir) and P. c. chabaudi (cir) and is related to the rifin family of P. falciparum. In P. c. 
chabaudi, 196 cir genes have been identified (28). However the role(s) of these genes 
in the immune response have not yet been established. 
 An immune response involving proinflammatory cytokines such as Tumour 
Necrosis factor (TNF) and Interferon-gamma (IFN-γ) is important in the clearance of 
the parasite from the host by activating macrophages to kill infected red blood cells 
(47). However over-exuberant responses are also known to lead to severe pathology. 
An overproduction of proinflammatory cytokines such as TNF, interleukin-1β (IL-1β) 
and IFN-γ is often observed in the pathology of severe malaria. These cytokines can 
induce large amounts of mediators such as nitric oxide, which can also cause 
pathology (15, 95). Larger amounts of TNF in the plasma have been shown to 
correlate with severe malaria (29, 30, 96), with higher concentrations of this cytokine 
being associated with cerebral malaria in children (97). This cytokine has been 
hypothesised to intensify sequestration by up-regulating adhesion molecules such as 
ICAM-1 and CD36 on the endothelium within blood vessels (98). Administration of 
antibodies against IFN-γ in mice infected with P. falciparum have also been shown to 
be able to prevent cerebral malaria and this was also associated with a down-
regulation of Tumor necrosis factor (99, 100).  
 Regulatory T cells (Tregs) have been shown to be induced in malaria infection, 
with studies in humans showing larger numbers of this cells in adults during times of 
increased malaria transmission in sub-Saharan Africa (101). As reviewed by Finney et 
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al. (102), these cells are not able to quell the large inflammation induced during the 
blood stage of malaria infection.  
 The cytokine, IL-10 is known to have anti-inflammatory roles (34, 103) and 
mice deficient in this cytokine and infected with P. c. chabaudi have been shown to 
exhibit symptoms of cerebral malaria such as haemorrhage in the brain and oedema 
(35, 63). Studies in mice by Li et al.  (104) revealed that administering antibodies 
against TNF in P. c. chabaudi infected IL-10 knockout mice decreased symptoms of 
increased pathology, demonstrating the ability of proinflammatory cytokines to 
cause pathology. IL-10 is produced by most types of differentiated CD4+ T helper cells 
including Th1 and Th17 cells, as well as other immune cells such as macrophages and 
dendritic cells to regulate cytokine production (105). Production of IL-10 by CD4+ T 
cells has been shown to be induced in P. c. chabaudi infection by IL-27 and provide 
protection from immunopathology (106). CD4+ T cells have also been found to 
produce IL-10 within P. yoellii infection (107). Further experiments also showed 
increased pathology when infected mice were treated with antibodies against 
another anti-inflammatory cytokine, Transforming Growth Factor β (TGF-β) (108).  In 
humans, IL-10 is produced at higher levels during malaria infection. T cells producing 
both IFN-γ and IL-10 are increasingly observed in children exposed to malaria (109).   
 CD4+ T cells are also able to differentiate into Th17 cells in the presence of IL-
6 and TGF-β, and these express the cytokines IL-17A, IL-17F and IL-22 (110). These 
cells have been shown to have roles combating infections such as Citrobacter 
rodentium and can also have pathogenic roles in inducing autoimmunity in 
experimental autoimmune encephalitis (111). Mastelic et al.  (112) investigated 
whether these cells play a role in malaria infection. Although increases in IL-17A and 
IL-17F were observed in the liver during P. c. chabaudi infection in C57BL/6 mice, no 
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significant differences were observed in pathology due to the loss of IL-17 in P. c. 
chabaudi infection. In mice lacking IL-22, however, severe pathology was observed 
during P. c. chabaudi infection.  IL-17 producing CD4+ T cells have been seen to be 
activated in P. berghei and P. yoellii infections but their role has not been identified 
(113). 
 
1.7 Interleukin-22  
A study examining the effect of polymorphisms in the IFNG gene and its neighbours, 
which include IL22 and IL26, in resistance and susceptibility to severe malaria found 
two haplotypes within the IL22 gene that were associated with resistance and 
susceptibility to severe malaria (114). This provided the first suggestion that this 
cytokine may play a role in protection from severe disease in malaria infection. 
Mastelic et al.  (112) also showed that mice deficient in IL-22 backcrossed for 3-5 
generations on C57Bl/6 (NIMR), developed a severe infection with 50% mortality, and 
significantly greater weight and temperature loss when infected with P. c. chabaudi 
AS. These were unexpected findings given what is known about this cytokine.  
 The cytokine, interleukin-22 is a member of the IL-10 family of cytokines, 
which also includes IL-19, IL-20, IL-24 and IL-26 (115). Originally known as Interleukin-
10 related T Cell-Derived Inducible Factor (IL-TIF), it was first discovered to activate 
the transcription factors, signal transducer and activator of transcription factors 1 
and 3 (STAT-1 and STAT-3) in mesangial and neuronal cell lines (116). In humans, the 
gene for this cytokine is located on chromosome 12 adjacent to the IFNG gene. In 
mice it is also located next to the IFNG gene but on chromosome 10, in the C57BL/6 
and 129 strains of mice this gene has been observed to be duplicated (117).  
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 Unlike most cytokines, the membrane-bound receptor for IL-22 is only 
expressed on non-haematopoietic cells such as hepatocytes and other epithelial cells 
in the lungs, kidney and gut (118). This receptor, known as IL22RA1, is a heterodimer 
of IL-10R2 and IL-22R1 (119, 120). IL-22 has a high affinity for the IL-22R1 subunit but 
a very low affinity for the IL-10R2 subunit. The IL-10R2 subunit, although, has an 
affinity for the IL-22 and IL-22R1 complex suggesting that the IL-22 first binds to IL-
22R1 and then to IL-10R2 forming the complete activated functional receptor (121-
123). 
 The activation of the IL-22 receptor leads to activation of the JAK-STAT 
signalling pathway in which the tyrosine kinases Janus Kinase 1 (JAK1) and tyrosine 
kinase 2 (tyk2) phosphorylate and activate each other and go on to phosphorylate 
and activate other proteins particularly signal transducer and activation of 
transcription 3 (STAT3). IL-22 has also been shown to activate the MAP Kinase 
pathway (124).  
 
1.8 Cellular sources of Interleukin-22  
Various lymphocytes are able to produce IL-22, as summarised in figure 1.1. Amongst 
T cells, Th1 cells have been shown to secrete this cytokine in response to IL-12 
stimulation (125). Th17 cells were later revealed to express IL-22 in larger amounts 
(126). The transcription factor, aryl hydrocarbon receptor (AHR), is required for the 
expression of IL-22 in these cells (127). AHR has been also demonstrated to be 
important for IL-22 production in other cells such as group 3 innate lymphoid cells 
(128) 
 IL-23, secreted by dendritic cells is able to stimulate T cells and innate 
lymphoid cells to secrete IL-22 (126, 129, 130). The expression of the IL-23 receptor 
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is induced in cells such as Th17 cells by the cytokines TGF-β and IL-6 enabling the 
development of Th17 cells (131-133). The cytokine TGF-β is able to inhibit the 
production of IL-22 in Th17 cells through the activation of c-maf (134). The 
transcription factor, BATF has also been shown by ChIP analysis to bind to the IL-22 
promoter (135).   
 Apart from Th17 cells, Th22 cells are also known to express IL-22, but unlike 
Th17 cells do not express IL-17 or IFN-γ or possess the transcription factor, RORγT 
(136). In mice, γδ T cells are also known to express IL-22 with IL-17A and IL-21, similar 
to Th17 cells they also express RORγT (137, 138). CD8+ T cells can also secrete IL-22 
and this occurs in a subset now known as Tc22 as well as Tc17 cells (139). Natural 
Killer T (NKT) cells have also been shown to secrete IL-22 in the skin, intestine and 
lung (140). Innate lymphoid cells positive for RORγT and AHR (Group 3 ILCs) are also 
able to express IL-22. Myeloid cell populations such as neutrophils have been 
reported to produce this cytokine during colitis (141). 
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Through IL-22RA1, the functions of this cytokine are exerted and these include 
recruitment of proinflammatory cells, secretion of antimicrobial peptides and 
producing mediators to co-ordinate protection and repair of tissues in the epithelia 
(142). This cytokine also has a soluble receptor known as IL-22RA2 or IL-22 binding 
protein (IL-22BP), which antagonises and prevents tumorigenic effects this cytokine 
may have (143). It is able to bind IL-22 with a four-fold higher affinity than IL-22RA1 
(144). It has been shown to be produced by a subset of dendritic cells, with the largest 
amounts being produced in the spleen (145). In the colon, it is constitutively 
expressed at normal conditions to prevent colorectal cancer. When the epithelia at 
this site are damaged during inflammation, the expression of this binding protein is 
down-regulated via IL-18, thus allowing IL-22 to mediate its effects (146). More 
recent studies by Martin et al. (147) have demonstrated that expression of IL-22BP in 
Figure 1.2 The various cells that produce the cytokine IL-22 and the cytokines which 
induce this production, adapted from Sabat et al.  (108). 
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the intestine can increase significantly during inflammatory bowel disease, due to 
increased production by eosinophils, strongly suggesting that the protective role that 
IL-22 may play could be hindered due to the increased presence of this factor in this 
case.  
 
1.9 Known functions of Interleukin-22  
IL-22 can have proinflammatory roles by inducing release of chemokines and 
proinflammatory mediators from epithelial cells. It also stimulates release of 
antimicrobial peptides from tissues. IL-22 induces release of anti-apoptotic factors 
such as BCL-xL and BCL-2 which inhibit apoptosis (148). These actions are mediated 
through the activation of STAT3 and result in tissue protection and repair.  
 IL-22 appears to play no role in infection models such as Mycobacterium 
tuberculosis and the helminth parasite, Schistosoma mansoni as no difference was 
observed in the clearance of pathogen or in pathology on the loss of this cytokine 
(149, 150). It could be argued that this is not surprising as this cytokine has not been 
shown to target immune cells thus is not like to be directly involved in the immune 
response against this pathogens.  However, IL-22 does exert protective or pathogenic 
effects in various other models of infection and organ damage through exerting other 
roles in different organs, as summarised in table 1.1.   
 In the liver, IL-22 has protective roles in various models of induced acute 
hepatitis with agents such as Concanavalin A, carbon tetrachloride and liver injury 
with paracetamol overdose (151-154) as well as in regenerating liver tissue after 
partial hepatectomy (155). IL-22 also protects the liver during infections such as with 
Dengue virus (156). This protection may be exerted by the induction of anti-apoptotic 
proteins such Bcl-2 through the activation of STAT3 (157).  Although, IL-22 can also 
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have pathogenic roles through these same actions by promoting cell survival in 
hepatocellular carcinoma (158).  
 In the intestine, Turner et al.  (159), have recently shown that IL-22 protects 
the epithelia and aids expulsion of the helminth parasite, Nippostrongylus brasiliensis 
by mediating goblet cell hyperplasia. Observing elevated expression of mucins and 
decreased goblet cell staining in histological sections of IL-22 knockout mice revealed 
this. IL-22 ameliorates inflammation induced in the mouse colon by dextran sodium 
sulphate (DSS) through the activation of STAT3 leading to the expression of mucins 
from colonic epithelial cells (160). 
 IL-22 can, however, have pathogenic actions in the intestine during infection 
with oral cysts of Toxoplasma gondii in mice. It was discovered that il22-/- mice had 
significantly decreased small intestinal necrosis during the infection and this was 
associated with reduced levels of matrix metalloproteinase 2 (MMP2), an 
endopeptidase that regulates the extracellular matrix which is associated with colitis 
(161). This cytokine can induce the production of interleukin-18 from intestinal 
epithelial cells in this infection, contributing to defence against this parasite as well 
as increasing damaging inflammation (162). 
 IL-22 is able to influence the microbiota within the intestine.  Zenewicz et al.  
(163) demonstrated that through losing the production of antimicrobial peptides 
such as RegIIIγ, il22-/- mice have been revealed to have an increased susceptibility to 
colitis. This was associated, through the use of 16S rRNA gene-pyrosequencing, 
revealing alterations in the gut microbiota that were pathogenic when transmitted 
to wild type mice. IL-22 also regulates the fucosylation of intestinal epithelial cells by 
inducing production of the enzyme, Fut2 in epithelial cells, this can prevent the 
infection of tissue by bacteria such as Salmonella typhimurium (164, 165).  
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 In psoriasis, IL-22 plays a pathogenic role (166). Through STAT3 activation, IL-
22 upregulates production of β-defensins from keratinocytes (167) and recruits 
inflammatory cells through the chemokine, CXCL5 (168, 169). More recently, this 
cytokine has been revealed to also have beneficial roles in the skin. For example in 
fibroblast mediated wound repair. Il22-/- mouse were found to have abnormal wound 
healing due to reduced extracellular matrix production (170). IL-22 also plays a 
protective role in a mouse model of Leishmania infection by protecting epithelial cells 
in the skin. Infected il22-/- mice were demonstrated here to have reduced wound 
healing (171).  
 The epithelium of the lung is also protected by IL-22 during influenza infection 
(172, 173). It is also able to protect mucosal epithelial barriers in the lung from 
damage during infections such as with Klebsiella pneumoniae by inducing the 
expression of lipocalin-2, a protein which can limit bacterial growth (174). IL-22 
provided by γδ T cells can prevent harmful lung fibrosis after inflammation induced 
by infection with Bacillus subtilis (137) or by administration of bleomycin (175) by 
slowing down the rate of collagen deposition. However, IL-22 can have pathogenic 
proinflammatory roles in the airway after bleomycin-induced inflammation, this can 
be dependent on the presence of IL-17A (179).  
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 Protective Pathogenic 
Liver Acute Hepatitis, Dengue 
virus 
 (151-154, 156, 157) 
Hepatocellular carcinoma 
(176) 
Skin Wound repair (170) Psoriasis-like inflammation (130, 
177) 
Lung Influenza (172, 173)  
Airway inflammation (+/- IL-17A) (178, 179) 
Gut Helminth infections (159) 
(Turner et al. , 2013) 
Toxoplasma gondii (150, 161) 
(Munoz et al. , 2009; Wilson et al. , 
2010) 
Intestinal inflammation 
(160) 
Colorectal cancer (146, 158, 180) 
Pancreas Acute pancreatitis (181, 
182) 
 
Brain  West Nile Encephalitis (183), EAE 
(184) 
Table 1.1 summarises the protective and pathogenic functions mediated by IL-22 in 
various organs in different conditions.  
Acinar cells of the pancreas also express the membrane bound IL-22 receptor, IL-
22R1. This cytokine has been shown to be able to inhibit autophagy in the pancreas 
induced by cerulein (182). In the brain, IL-22 is involved in the pathogenesis of west 
Nile encephalitis through increasing recruitment of neutrophils by inducing 
expression of the chemokines, CXCL1 and CXCL5 from endothelial cells (183). It is also 
shown, along with IL-17A, able to disrupt the blood brain barrier allowing diffusion of 
proteins into the brain in experimental autoimmune encephalomyelitis (EAE), a 
model of multiple sclerosis (184). Although this cytokine does not have a role in the 
development of EAE, since il22-/- mice still succumb to illness (185). 
1.10 The role of Interleukin-22 in malaria infection 
A study examining the effect of polymorphisms in the IFNG gene and its neighbours, 
which include IL22 and IL26, in resistance and susceptibility to severe malaria found 
two haplotypes in the IL22 gene that were associated with resistance and 
susceptibility to severe malaria (114). This provided the first suggestion that this 
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cytokine may play an important role in protection from severe disease in malaria 
infection.  
 Mastelic et al.  (112) revealed further evidence of a role for this cytokine in 
malaria by infecting il22-/- mice on a C57BL/6 background with P. c. chabaudi AS. 
Although these mice were able to control parasitaemia, they progressed onto severe 
pathology shown by significant weight and temperature loss as well as 50% mortality. 
Il22-/- mice were shown to have a statistically significant increase of alanine 
transaminase (ALT) in the plasma, an enzyme whose increase in the plasma is a signal 
of liver damage. 
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1.11 Aims of this thesis  
The lack of interleukin-22 has been shown to result in increased pathology during P. 
c. chabaudi AS infection whilst not significantly affecting parasitaemia (112). Markers 
of liver damage being increased in this infection on the loss of IL-22 suggested that 
this might stem from an important role in this cytokine in protecting hepatocytes 
vulnerable during malaria infection. 
 Characterisation of the actions of the cytokine IL-22 detailed within this 
introduction reveal that IL-22 also has crucial functions at the epithelial surfaces of 
the lungs and in the intestine, where it is known to be expressed at higher levels 
constitutively (186).  It is therefore possible that the lack of IL-22 in these sites leads 
to increased pathology in P. c. chabaudi infections. This thesis aims to:  
1) Understand how IL-22 could protect against severe pathology in the erythrocytic 
stage of malaria infection by analysing its production in different organs and cells 
during P. c. chabaudi infection. This shall be done by: 
a) Analysing expression of il22 mRNA in the spleen, liver, lungs and small and 
large intestine during P. c. chabaudi infection. 
b) The cells producing IL-22 in spleen, liver, lung and gut will be identified using 
an  Il-22cre x R26ReYFP fate reporter mouse (186). By employing the use of 
this mouse  through the use of flow cytometry in the relevant organs, 
increases in IL-22  producing cell  populations can be documented.  
2) The effects of the lack of IL-22 in P. c. chabaudi infection shall be ascertained 
through the use of il22-/- mice that have been backcrossed onto C57BL/6 (NIMR) at 
least 8 times, and using appropriate NIMR C57BL/6 controls.  
3) A significant increase in ALT in il22-/- mice suggests this increase in mortality of il22-
/- mice after infection with P. c. chabaudi may be due to increased liver damage (112). 
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Histopathology and other measurements of pathology in the liver, lungs and intestine 
will be carried out to determine whether there are obvious changes in histopathology 
resulting from a lack of IL-22 in P. c. chabaudi infected mice. 
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2. Materials and Methods 
2.1  Buffers  
 
FACS buffer 
Phosphate buffered saline (PBS) pH 7.2  
Fetal calf serum (FCS) 2% PAA Laboratories, GmBH 
Sodium azide (NaN3) 0.05%  
  
Complete Iscove's medium  
Iscove’s modified 
Dulbecco’s medium 
(IMDM) 
 Sigma 
Foetal Bovine Serum 10% PAA  
β-mercaptoethanol 0.05mM Gibco 
L-glutamine 2mM Gibco 
Sodium Pyruvate 0.5 M Sigma 
HEPEs Buffer 6mM  Gibco 
Streptomycin 100 μg ml−1  Gibco 
 
Magnetic-activated cell sorting (MACS) buffer  
Phosphate buffered saline (PBS) pH 7.2 Gibco, Invitrogen 
Foetal calf serum (FCS) 2%  PAA Laboratories, GmBH 
 
ELISA Blocking buffer 
Phosphate buffered saline (PBS)   
BSA 1% Sigma-Aldrich 
Tween-20 0.05% Sigma-Aldrich 
Sodium azide (NaN3) 0.05%  
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ELISA Washing buffer  
Phosphate buffered saline (PBS)  
Tween-20     0.05% 
 
ELISA Detection buffer 
Phoshphate buffered saline (PBS)   
BSA 1% Sigma 
Sodium azide (NaN3)  0.05%  
 
ELISA Diethanolamine buffer 
Phosphate buffered saline (PBS)  
Diethanolamine 5% 
MgCl2 2mM 
Sodium azide (NaN3) 0.05% 
 
Giemsa staining buffer  
Na2HPO4  30g (VWR) 
KH2PO4 6g (VWR) 
Distilled Water  1L  
 
2.2  Antibodies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marker Fluorochrome Clone Source 
CD45.2 APC-Cy7 104 Biolegend 
TCRβ  APC H57-
597 
APC-Cy7  H57-
597 
γδTCR BV421 (Brilliant violet 
421) 
GL3 
CD4 PerCP RM4-5 
CD8 PE-Cy7 53.67 
   
NK1.1 PE (phycoerythrin) PK136 
IL-22 APC (Allophycocyanin) IL22JOP eBioscience 
Table 2.1 shows the antibodies used for flow cytometry analysis of eYFP+ cells in the 
fate reporter mouse and for intracellular cytokine staining of IL-22. 
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2.3  Mice  
Animal experiments were conducted according to Home Office regulations. All mice 
were bred under specific pathogen free conditions at the Francis Crick Institute, Mill 
Hill Laboratory, London. Interleukin-22 knockout  (il22-/-) mice on a C57BL/6 
background were originally provided by Jean-Christophe Renauld (Ludwig Institute 
for Cancer Research) were generated by targeting of the exons 1-3 with a neomycin-
resistant gene (185). These il22-/- mice have been backcrossed onto NIMR C57BL/6 
mice across more than eight generations. Littermate wild type controls were used 
alongside il22-/- mice. IL-22 fate reporter mice (IL-22cre+/- x Rosa26ReYFP) mice (187, 
188) that allow the observation of cells, which have expressed IL-22 were provided 
by Brigitta Stockinger (The Francis Crick Institute). These mice were generated by 
crossing mice heterozygous for having cre recombinase at the IL-22 gene locus with 
mice that had eYFP at the Rosa26 promoter.  
2.4 Infection with Plasmodium chabaudi chabaudi  
Mice were infected with Plasmodium chabaudi chabaudi AS (P.c.c. AS) or Plasmodium 
chabaudi chabaudi CB (P.c.c. CB) by intraperitoneal injection. For injection of blood 
stage parasites, 10,000 infected red blood cells were injected into each mouse. Mice 
were also infected with Plasmodium chabaudi through the mosquito using a protocol 
optimised by Spence et al.  (64). To do this, “feeder” mice were injected with 10,000 
P. c. chabaudi infected erythrocytes intraperitoneally and after 14 days; mice with a 
suitable number of gametocytes (more than 0.1%) were fed to female Anopheles 
stephensi mosquitoes. Eight days later, oocysts were quantified in the midgut of the 
mosquito to monitor the progress of the parasite through its life cycle. At 15 days, 
sporozoites within the salivary glands of the mosquitoes were counted and the 
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infection was transmitted to experimental mice by allowing 20 mosquitoes to feed 
on each experimental mouse. 
 In all infections, parasitaemia was analysed by counting of thin blood smears 
by making a small nick at the tip of the tail and smearing a drop of blood on a 
microscope slide. After fixing with 100% methanol (BDH) these slides were stained 
with Giemsa solution (10% Giemsa stain (VWR) and 10% Giemsa staining buffer for 
25 minutes. Parasitaemia was counted using bright-field microscopy with a 100x 
objective and calculated as the number of infected erythrocytes in an observed 
number of erythrocytes as a percentage. 
 Weight and temperature were monitored through the course of infections. 
Red blood cell counts were measured using a Vetscan HMII analyser (Abaxis). In order 
to do this 5 μl of blood was taken from the tip of the tail and diluted 1:10 in KGS 
containing heparin.  
 
2.5 Analysis of markers of pathology in plasma 
Under terminal anaesthesia by intraperitoneal injection of pentoject (Animal Care), 
blood samples were collected via cardiac puncture. Blood samples were also 
obtained at time points during the infection by tail vein bleed. These blood samples 
were then centrifuged twice and plasma was immediately frozen on dry ice after 
retrieval. Alanine Transaminase (ALT), Aspartate transaminase (AST), lactate and urea 
levels were measured using a cobas C111 chemistry analyser (Roche). Samples 
collected at day 0 and 5 of infection were diluted (1:10) in PBS (Gibco) and infected 
samples, collected at days 7 and 9, were similarly diluted in PBS (1:100).  
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2.6 Broncheoalveolar lavage fluid analysis 
To retrieve broncheoalveolar lavage (BAL) fluid, mice were terminally anaesthetised, 
lungs were cannulated and 500μl of PBS (Gibco, invitrogen) was injected and 
retrieved. These samples were immediately placed on ice, centrifuged at 900g for 2 
minutes at 4°C. Supernatants were obtained and subsequently frozen at -80°C.  
 IgM levels in the BAL fluid were quantified using ELISA. Maxisorp 
immunoplates (Nunc) were coated with a goat anti-mouse IgM unlabelled antibody 
(Southern Biotech) diluted to 1μg/mL in PBS and incubated overnight at 4°c. All 
incubations were performed with the plate within a humidity chamber. The plates 
were then blocked with blocking buffer for 2 hours at 37°c and washed with washing 
buffer. Samples of BAL fluid supernatants in duplicates were then serially diluted in 
blocking buffer, along with a standard of purified IgM (Sigma Aldrich) also serially 
diluted starting from 16 μg/mL. IgM was detected using a secondary goat anti-mouse 
IgM antibody labelled with alkaline phosphatase (Southern Biotech), diluted at 
1μg/mL in detection buffer and incubated for 1 hour at room temperature. The 
substrate; para-nitrophenylphosphate (Sigma) was subsequently added and the 
plates were allowed to develop in the dark. Optical density (O.D.) was read using the 
Tecan Infinite M1000 spectrometer plate reader at a wavelength of 405nm. 
Concentrations were interpolated from the standard curve fitted to a four-parameter 
sigmoidal (logistic) model.  
 Protein levels in BAL fluid were measured using the Bradford assay. For each 
sample, 25 μl of BAL fluid was added to 125 μl PBS and a serial dilution was made of 
this with a dilution factor of 3. A standard was made serially diluting Bovine serum 
albumin (Sigma) in PBS starting from 133μg/mL. Bradford reagent (Bio-Rad) was 
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added to these dilutions and absorbance was measured using a Tecan Infinite M100 
spectrometer at 595nm.  
 
2.7 Histopathological analysis 
After terminal anaesthesia, lungs were inflated by cannulation through the trachea 
and injection of 4% paraformaldehyde (VWR). They were then fixed in 
paraformaldehyde along with the liver, gut, spleen, kidney and brain. After fixation 
for at least 24 hours, these organs were then embedded in wax, sectioned and 
stained by the histology facility at the Francis Crick Institute, Mill Hill Laboratory. 5μm 
sections were taken and stained with haematoxylin and eosin (H&E). Sections of 
small intestines were also stained with Alcian Blue – Periodic Acid Schiff (AB-PAS) to 
identify goblet cells. Images were analysed with the use of a VS120 virtual slide 
scanning system (Olympus).  Pathology was scored by a pathologist according to 
severity grading schemes described in Shackleford et al. (189). 0 means no pathology 
was observed, 1 denotes minimal pathology observed, 2 slight, 3 Moderate, 4 
Moderately severe and 5 for severe. In the liver, this severity was defined by 
recording the level of focal necrosis, as well as numbers of kupffer cells and 
inflammatory cell foci were analysed. In the Lungs, the level of increased cellularity 
of the alveolar septae was defined.  
2.8 Isolation of mononuclear cells.  
To isolate mononuclear cells from the spleen, this organ was mashed through a cell 
strainer and washed with complete IMDM. Red blood cell lysis buffer (Sigma) was 
used to remove erythrocytes and after washing, the suspension of mononuclear cells 
was resuspended in complete IMDM. Whole livers and lungs were excised and 
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immediately placed into Iscove’s modified Dulbecco’s medium (IMDM) (Sigma) 
supplemented with 10% fetal bovine serum (PAA), 0.05 mM B-mercaptoethanol 
(Gibco), 2 mM L-glutamine (Gibco), 0.5 mM sodium pyruvate (sigma), 6mM Hepes 
buffer (Gibco) 100 U ml−1 penicillin and 100 μg ml−1 streptomycin (Gibco). After 
mincing and digestion for an hour in liberase (Roche), they were then mashed 
through a 70μm cell strainer and washed in medium. Liver mononuclear cells were 
extracted after suspension in 40% Percoll (GE Healthcare Life Sciences) and then 
washed again. With the use of red blood cell lysis buffer (Sigma), erythrocytes were 
removed from the single cell suspensions of lungs and livers. These cells were then 
washed again and counted using trypan blue dye (Sigma) to exclude dead cells.   
 To isolate mononuclear cells from the small and large intestine lamina 
propria, these organs were excised and placed in ice cooled PBS containing 10mM 
HEPES buffer. Faeces and mucus were removed and the tissue was cut into 2cm 
pieces. Tissue was placed in IMDM containing 10mM dithiotreitol, 1% FCS, penicillin, 
streptomycin, L- glutamine and 10mM HEPES buffer. To remove epithelial cells, tissue 
was placed in a 37°c incubator whilst shaking at 225rpm. The supernatant was then 
removed by passing tissue over a tea strainer. The tissue was then digested in IMDM 
containing DNase (5mg/mL) and Liberase TL (Roche) and a mixture of collagenases. 
Small intestine tissue was digested for 15 minutes and Large intestine for 30 minutes 
in a shaking incubator at 37°c and 225 rpm. The digested tissue was then mashed 
through a 100 μm cell strainer and washed with ice cold complete IMDM. This 
suspension was then resuspended in 40% percoll (GE Healthcare Life Sciences) and 
mononuclear cells were separated and resuspended in complete IMDM.    
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2.9 Positive selection of CD45+ lymphocytes by magnet-activated cell sorting 
(MACS) 
Single cell suspensions of the liver and lung were counted and resuspended in MACS 
buffer. These were then incubated with CD45 microbeads (Miltenyi Biotec), Fc block 
(anti-CD16/32) (BD biosciences) and anti-CD45 PE-Cy7 (Biolegend) for 20 minutes. 
After washing and resuspension in MACS buffer, these cell suspensions were then 
transferred onto pre-wetted LS columns (Miltenyi Biotec). After the suspension was 
allowed to flow through, it was washed with MACS buffer and magnets were 
removed. CD45+ cells were then positively selected and frozen in TRI-Reagent for 
subsequent RNA extraction and qRT-PCR analysis. Through the use of flow cytometry, 
the correct positive selection of CD45+ cells was confirmed.   
2.10 Analysis of eYFP+ lymphocytes by Flow Cytometry 
To analyse eYFP positive lymphocytes in the IL-22 fate reporter mice, mononuclear 
cells were surface stained with fluorochrome-conjugated antibodies (all purchased 
from Biolegend) for the following markers; CD45.2 APC-Cy7, TCRβ APC, γδ TCR 
BV421, CD4 PerCP, CD8 PE-Cy7, NK1.1 PE. Dead cells were excluded from analysis 
using the Zombie Aqua BV510 viability dye (Biolegend).  
 Cells to be stained intracellularly were incubated for 4 hours in complete 
IMDM with the Brefeldin A containing solution, Golgi Plug (BD Biosciences) and 
stimulated with Phorbol 12-myristate 13-acetate (PMA) (Sigma) and ionomycin 
(Sigma). Fc block was used to prevent unspecific binding. To analyse populations of 
T-cells secreting IL-22, cells were stained with the following fluorochrome-conjugated 
antibodies; anti-TCRβ APC-Cy7, γδ anti-TCR BV421, anti-CD4 PerCP, anti-CD8 PE-Cy7, 
anti-NK1.1 PE (all from Biolegend). After fixation with 2% paraformaldehyde (Sigma) 
for 20 minutes and permeabilization with 0.1% octylphenyl-polyethylene glycol 
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(Sigma), cells were stained intracellularly with anti-IL-22 APC (Affymetrix Bioscience) 
and washed with FluoroFix buffer (Biolegend). Non-specific binding by this antibody 
against IL-22 was controlled for with the use of an isotype Rat IgG2a APC antibody 
(eBioscience). Samples were acquired using the BD FACS suite software on a BD verse 
flow cytometer (BD Biosciences) and data was analysed using Flowjo X software 
(Treestar Inc.) 
2.11 Analysis of gene expression by qRT-PCR 
To analyse gene expression through quantitative real time polymerase chain reaction 
(qRT-PCR), spleen, lungs, liver and small and large intestine were excised and 
immediately homogenised in TRI-Reagent (Life Technologies) using a Polytron System 
PT 1300 D (Kinematic AG). Aliquots of organ homogenates were made and then snap 
frozen. For the lungs and liver, mononuclear cells were also isolated as previously 
described and within these suspensions CD45+ lymphocytes were enriched through 
magnetic sorting (MACS) using CD45 microbeads (Miltenyi-Biotec) through manual 
cell separation using columns. CD45+ enriched cell populations were then snap 
frozen in TRI-Reagent. 
 RNA was extracted from samples using the RiboPureTM kit (Life Technologies) 
according to the manufacturer’s instructions. Concentration of RNA were measured 
using the NanoDrop 1000A spectrophotometer. Measuring the ratio of absorbance 
at 260 and 280 nm ensured purity. 2 μg of RNA was used to synthesise cDNA with the 
use of an Omniscript reverse transcription PCR kit (Qiagen).  
 Quantitative (q) RT-PCR was performed using the LightCycler Real-Time PCR 
assay (Roche). Probes from the Universal Probe Library were used which were 
designed to be suitable for the primers targeting hprt, il22 and il22bp. The following 
primers (obtained from Sigma-Aldrich) were used hprt forward: 5'-
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TCCTCCTAGACCGCTTTT-3' reverse: 5'-CCTGGTTCATCATCATCGCTAATC-3'; il22 
forward: 5'-TTTCCTGACCAAACTCAGCA-3' reverse: 5'-TCTGGATGTTCTGGTCGTCA-3'; 
il22bp forward: 5'-ACAACAGCATCTACTTTGTGCAG-3' reverse: 5'-
CCCCCAGCAGTCAACTTTAT-3'. Expression of il22 and il22bp was normalised to hprt 
and reactions were performed on a LightCycler 480 II (Roche). 
 In order to validate the il22 primer set, the amplicon generated from qRT-PCR 
was analysed by gel electrophoresis using 2% metaphor agarose (Lonza) and 
confirmed to be of the expected size.   
2.12 Statistical analysis 
Data was analysed using GraphPad prism version 6.0 for Mac OS X, GraphPad 
Software, La Jolla California USA, www.graphpad.com.  Differences in median were 
deemed statistically significant with a P value less than 0.05 and established using the 
Mann-Whitney U test or the Kruskal-Wallis test were more than two groups were 
analysed. Statistically significant values are denoted by (*) for less than 0.05, (**) for 
less than 0.01 and (***) for less than 0.001. Statistically insignificant differences are 
denoted by (ns). 
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3. Results - Analysing the expression of IL-22 in Plasmodium 
chabaudi infection 
3.1 Expression of il22 mRNA in P. c. chabaudi infection  
In order to answer whether there is a role for IL-22 in this mouse model of malaria 
infection, it is important to observe if there are any changes in the expression of this 
cytokine at various time points, during the acute phase, of this infection. This analysis 
was first performed in the spleen, a lymphoid organ known to have important 
functions in malaria infection (190). Changes in IL-22 gene expression were also 
investigated in the liver, where previous studies in malaria infection suggested there 
is increased damage in mice that lack IL-22 (112), and where it is known that P. c. 
chabaudi parasites sequester (32). The lungs and the intestine are organs where IL-
22 has been shown in various scenarios to have an important role (121), thus these 
organs were also included in order to investigate the role of this cytokine here.  
 
To detect il22 mRNA in the spleen, whole organ homogenates were made throughout 
a time course of the acute P. c. chabaudi chabaudi AS infection in C57BL/6 mice. RNA 
was extracted and cDNA synthesised for use in qRT-PCR to detect IL-22 expression. 
As shown in figure 3.1, there is a slight trend for increase in il22 mRNA expression at 
Figure 3.1 Levels of il22 mRNA detected in the spleens of C57BL/6 mice during 
a time course of acute P. c. chabaudi infection, expressed as fold change 
relative to the housekeeping gene, hprt. Statistical significance analysed by the 
Kruskal-Wallis test (n=4). Lines show the median with the interquartile range. 
Representative of 1 experiment.  
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day 3 of P. c. chabaudi infection, although the median level of expression did not 
change significantly. After day 5, the expression of this cytokine appears to decrease 
further. 
   
In order to detect il22 mRNA reliably in the lungs and liver, it was necessary 
to excise mononuclear cells from these organs and enrich CD45+ lymphocytes by 
positive selection using magnetic-associated cell sorting (MACS) before freezing 
these in TRI-Reagent for RNA extraction, cDNA synthesis and qRT-PCR analysis.  
 As can be observed in figure 3.2, at three stages during this process, cells were 
stained and analysed through flow cytometry to ensure correct and sufficient 
enrichment of CD45+ lymphocytes. Prior to mononuclear cells being sorted by MACS, 
it can be observed that there is a significant population of CD45- cells in the lungs and 
even more so in the liver. The MACS flow through shows the cells, which did not 
remain in the MACS columns, a large majority of these are shown to be the CD45- 
Figure 3.2 Flow cytometric analysis to validate enrichment of CD45+ lymphocytes through 
the use of MACS, performed on mononuclear cells isolated from the lungs and liver. 
Populations of CD45 positive and negative cells before and after MACS are revealed as well 
as cells in the flow through which were not positively selected. 
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cells. It can be observed in figure 3.2 that this process was able to enrich CD45+ 
lymphocytes successfully, increasing the possibility of measuring mRNA expression 
of il22 by removing RNA from other cells such as epithelial cells, which would not be 
expressing this cytokine.   
This process was carried out in a time course of acute P. c. chabaudi AS 
infection at days 0, 5, 7 and 10. As can be observed in figure 3.3 there is an increase 
in the total mononuclear cells as well as the CD45+ lymphocytes as the infection 
progressed in the liver and lung. In the liver between days 0 and 10, the number of 
total mononuclear cells almost triples. Although the number of CD45+ cells is similar 
between days 0 and 5 of infection, after this time point there is a sharp increase in 
the number of these cells. In the lungs it can also be observed that there is not much 
change in the total mononuclear cells or cells that are CD45+ between days 0 and 5. 
However after this time point, there is an increase in total mononuclear cells, with a 
Figure 3.3 show numbers of total mononuclear cells as well as the numbers of CD45+ 
cells that were sorted from the lungs and liver by MACS. Lines represent the median with 
the interquartile range. (Statistical significance was measured by the Kruskal-Wallis test)  
(n =5). Representative of 1 experiment. 
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peak at day 7 and in CD45+ cells there is an increase until day 10 of infection.   The 
Kruskal-Wallis test showed changes in the median in all 4 cases were statistically 
significant. In the Liver total monononuclear cells (p=0.017) and CD45+ cells 
(p=0.0016) as well as in the lung total mononuclear cells (p=0.004) and CD45+ cells 
(p=0.002).  
 The isolated CD45+ lymphocytes were frozen in TRI-Reagent for RNA 
extraction to analyse the expression of il22 mRNA at these time points.  As can be 
observed in figure 3.4, in the lungs there was no significant change in the median 
expression of il22 mRNA from day 0 to day 5 of P. c. chabaudi AS infection. However, 
after day 5, there was a decrease in il22 mRNA. This decreased level of expression 
maintained at day 10. The Kruskal-Wallis test found this change to be significant 
(p=0.0025). In the liver, also shown in figure 3.4, il22 mRNA increased significantly by 
day 5 of infection. After this point, levels of expression were found to decrease by 
day 7, lower than the original levels detected in the naive mice, and this remained as 
low at day 10. These change were also found to be significant by the Kruskal-Wallis 
test (p=0.025).   
 
 
Figure 3.4 show levels of il22 mRNA detected in the lungs and liver during 10 days of P. c. 
chabaudi AS infection. Lines show the median with the interquartile range. Statistical 
significance was measured using the Kruskal-Wallis test    (n=5). Representative of 1 
experiment. 
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Analysis of the expression of il22 mRNA was also undertaken in the intestine during 
P. c. chabaudi AS infection. Total RNA was extracted from whole organ homogenates 
of the duodenum of the small intestine as well as the colon, which were snap frozen 
in Tri-Reagent (Ambion). Figure 3.5 shows the results of this analysis in these organs. 
As can be observed, in the small intestine there is no significant change in the median 
expression of il22 mRNA until day 7. After this time point the expression of il22 
decreases significantly with a slight trend for increase by day 12 of the infection. 
These changes were shown to be significant (P=0.03, Kruskal-Wallis test). In the large 
intestine, there was a slight trend for increase between day 0 and day 5 of P. c. 
chabaudi AS infection. After day 5 of the infection the median level of il22 mRNA 
expression was slightly reduced till day 12 of infection. These changes in the median 
were not shown to be significant (p=0.22, Kruskal-Wallis test).  
 
 
3.2 Analysing the mRNA expression of IL-22 Binding protein (IL-22BP) 
Apart from its membrane-bound receptor, IL-22R1, IL-22 is known to have a second 
receptor known as IL-22 binding protein, which acts as a soluble antagonist. Studies 
Figure 3.5 shows analysis of il22 mRNA in the small and large intestine during 12 days of 
P. c. chabaudi AS infection. Values expressed as fold change relative to hprt. Bars 
represent the median level of expression at each time point. Statistical significance 
analysed by Kruskal-Wallis test.  (n =5). Representative of 1 experiment. 
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in other infection models such as influenza have found expression of this factor can 
change, impacting the ability of IL-22 to perform its functions (173).  
 To investigate whether the expression of IL-22BP is modulated within P. c. 
chabaudi infection to allow the cytokine to perform its actions, qRT-PCR was 
performed in cDNA synthesised from RNA isolated from whole organ homogenates 
of the spleen, lungs, liver and colon through a time course of acute P. c. chabaudi 
infection. Figure 3.6 shows the results of this analysis. As can be observed in the 
spleen, there is an early trend for increase by day 1 of infection, however this was 
not significant. After day 1, the median level of il22bp mRNA is reduced by day 5 of 
P. c. chabaudi infection with levels remaining low till day 12. This change was shown 
to be statistically significant by the Kruskal-Wallis test (p=0.0001). In the liver 
(p=0.78), lungs (p=0.78) and colon (p=0.38), the median level of il22bp expression can 
be observed to not change significantly in acute P. c. chabaudi infection. 
Figure 3.6 shows analysis of il22bp mRNA in whole organ homogenates of the spleen, 
lungs, liver and colon. Lines show the median level of il22bp mRNA expression with the 
interquartile range (Statistical significance was measured by the Kruskal-Wallis test) (n=5). 
Representative of 1 experiment. 
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3.3 Analysing expression of IL-22 through Intracellular cytokine staining in P. c. 
chabaudi infection 
As well as analysing the mRNA expression of the cytokine, IL-22, another important 
aim was to analyse its cellular production during this infection. In order to deduce 
which cells produce this cytokine and in which organ or tissue, flow cytometry in 
combination with intracellular cytokine staining was used. This was attempted in the 
liver, an organ strongly suggested by work of Mastelic et al.  (112) to be a site where 
IL-22 may play a role during malaria infection.   
 Mononuclear cells were isolated from the liver by density centrifugation in 
37% percoll after mashing through a cell strainer and performing a red blood cell lysis. 
This was done in naive C57BL/6 mice as well as at day 7 of P. c. chabaudi AS infection. 
Cells were either not stimulated or stimulated with PMA and ionomycin. To ensure 
that signals revealing the presence of IL-22 were due to the intracellular staining of 
this cytokine, two negative controls were used. A "fluorescence-minus-one" (FMO) 
control, which contained all other fluorochrome-conjugated antibodies in the 
staining panel except the antibody against IL-22, was also used. An isotype control 
that was a fluorochrome-conjugated antibody with the same fluorochrome used to 
label IL-22 but did not have specificity for mouse protein was also employed. As can 
be observed in the dot plots within figure 3.7, in the FMO and isotype controls there 
was no discernible positive staining in these two negative controls. However, in the 
stimulated as well as the non-stimulated lymphocytes from the liver of naive C57BL/6 
mice there were a very few cells that were clearly producing IL-22.  
 48 
 
 
Very few cells were observed to be positive for IL-22 through intracellular staining for 
iL-22 in the liver unless the staining was performed on lymphocytes from the liver of 
infected mice and this staining was also not very distinct. This suggested that it might 
prove difficult to analyse cytokine-producing cells in the relevant organs through a 
full time course of acute P. c. chabaudi infection by intracellular cytokine staining. 
Thus the use of IL-22 fate reporter mouse was employed, and analysed by flow 
cytometry.  
 
Figure 3.7 shows dot plots from the intracellular cytokine staining for IL-22 in liver 
lymphocytes from C57BL/6 isolated whilst naive and at day 7 of P. c. chabaudi AS 
infection. These lymphocytes were stained after stimulation with PMA and ionomycin or 
without any stimulation. Fluorescence minus one (FMO) and isotype controls are also 
shown. 
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3.4 Analysing expression of IL-22 in P. c. chabaudi infection with the use of an IL-22 
fate reporter mouse  
As efforts with intracellular cytokine staining proved difficult, an IL-22+/-cre x R26ReYFP 
fate reporter mouse was infected with P. c. chabaudi and the eYFP positive cells were 
analysed by flow cytometry. Ahlfors et al. (186) generated this mouse  which has the 
gene for cre recombinase at one allele of the IL-22 gene locus. Thus when the IL-22 
gene is switched on, cre recombinase is expressed and this enzyme targets a floxed 
STOP cassette in front of the Rosa26 promoter, allowing the expression of the gene 
for eYFP which is located here. This eYFP expression is permanent in these cells, even 
after they may have stopped expressing IL-22. However, this mouse can contribute 
vital details into whether IL-22 is increasingly expressed during P. c. chabaudi 
infection, which cells produce it and in which organs.  
 These IL-22 fate reporter mice were infected with P. c. chabaudi AS and at 
various time points mononuclear cells were isolated from the spleen, liver, lung as 
well as the small and large intestines. Flow cytometry was used to analyse eYFP+ 
lymphocytes, which were also stained with fluorochrome-conjugated antibodies in 
order to characterise which lymphocytes had produced or were producing IL-22. As 
shown in figure 3.8, through the use of flow cytometry, single live lymphocytes were 
gated on and analysed for their expression of eYFP. Single cells were selected by 
gating on the edge of the population shown when forward scatter height (FSC-H) was 
placed against forward scatter area (FSC-A). Live cells were selected by gating on the 
cells that did not stain positive for dead cell staining and within this population, 
lymphocytes were selected. Within these cells, those positive for CD45 were gated 
on and their expression of eYFP was then analysed.  
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In the spleen it was observed that, in naive mice, there was already a very small 
proportion of lymphocytes that were positive for eYFP. As can be seen in figure 3.9, 
eYFP+ cells were only 0.003% of the lymphocyte population.  While the proportion 
eYFP+ cells appeared to decrease significantly over days 5 and 7 (p=0.005, Kruskal-
Wallis test), the total numbers of these cells in the spleen did not change significantly 
through the three time points (p=0.34, Kruskal-Wallis test).  
 
Figure 3.8 shows the gating strategy used to select single live lymphocytes that were eYFP+ 
for analysis through flow cytometry performed on mononuclear cells isolated from the small 
intestine of an IL-22 fate reporter mouse.  
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A higher proportion and number of lymphocytes in the liver were found to be positive 
for eYFP than in the spleen. As shown in figure 3.10, the median percentage of 
lymphocytes from naive mice was 0.015% and this did not change at day 5. Although 
at day 7, the percentage of eYFP+ lymphocytes dropped and remained low at day 10 
of P. c. chabaudi infection. These changes in the median were not found to be 
significant (p=0.08, Kruskal-Wallis test). There were no significant changes in the 
median total numbers of these cells in the liver (p=0.48, Kruskal-Wallis test).  
 
Figure 3.9 shows the proportion and total cell numbers of lymphocytes found to be positive 
for eYFP in the spleen whilst naive and at day 5 and 7 of P. c. chabaudi AS infection. Lines 
show the median with the interquartile range. Statistical significance measured using the 
Kruskal-Wallis test (n>5) Representative of 1 experiment. 
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 Figure 3.11 shows that there were a small number of eYFP+ cells already in the lungs 
of naïve mice.  At day 5 of infection, this cell population increased both in percentages 
and total numbers. However after this time point, the levels of eYFP+ lymphocytes 
decreased significantly by the peak of P. c. chabaudi infection at day 7 and this was 
reflected in both the percentages and the total cell numbers. Both in the percentages 
(p=0.02) and total numbers (p=0.01), the changes in the median were found to be 
significant by the Kruskal-Wallis test. 
 
In the study described by Ahlfors et al.  (186), the lamina propria of the small and 
large intestine were found to contain the largest numbers of eYFP+ lymphocytes in 
Figure 3.10 shows the percentages as well as total numbers of lymphocytes found to be 
positive for eYFP in the Liver whilst naive and at days 5, 7 and 10 of P. c. chabaudi infection 
Lines represent the median level of expression with the interquartile range (n>3) Statistical 
significance was measured by the Kruskal-Wallis test. Representative of 2 experiments. 
Figure 3.11 shows the percentages and total numbers of eYFP+ lymphocytes in the lungs 
whilst naive and at days 5, 7, 8 and 10 of P. c. chabaudi infection. Lines represent the 
median level of expression with the interquartile range (Statistical significance was 
measured by the Kruskal-Wallis test) (n>5). Representative of 1 experiment. 
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the naive fate reporter mice. Studies here found similar numbers of eYFP+ 
lymphocytes in the naive mice. As can be observed in figure 3.12, a similar percentage 
of lymphocytes that were eYFP+ were found in both these organs, but there were no 
significant changes in the median percentages of the eYFP lymphocytes during acute 
infection in the small (p=0.77) and large (0.67) intestine by the Kruskal-Wallis test.  
There was an increase in the median cell number in the small intestine and this 
change was found to be significant (p=0.01, Kruskal-Wallis test). 
 
 
3.4 Characterising eYFP+ cells in the IL-22 fate reporter mouse in P. c. chabaudi 
infection  
 
After analysing levels of eYFP+ lymphocytes in the various organs during P. c. 
chabaudi infection, a pertinent question to ask was what identities made up these 
cells. Whether these were cells normally associated with IL-22 production such as T 
cells and innate lymphoid cells and how they may change during infection.  In figure 
Figure 3.12 shows the percentage as well as total numbers of lymphocytes that were 
observed to be eYFP+ whilst naive and at days 5, 7 and 10 of P. c. chabaudi infection. Lines 
represent the median level of expression with the interquartile range (Statistical significance 
was measured by the Kruskal-Wallis test) (n>3) Representative of 1 experiment.  
 54 
3.13, the gating strategy used to investigate which cell populations made up the 
eYFP+ lymphocytes is shown. After selecting on the eYFP+ lymphocytes, they were 
then plotted based on their expression of TCRβ. Of the TCRβ+ eYFP+ lymphocytes the 
proportion of these that were CD4+ or CD8+ was also recorded. Within the TCRβ- 
eYFP+ lymphocytes, the proportion of these that were positive for γδ TCR was 
surveyed and for those negative for this receptor, the expression of NK1.1, a marker 
for Natural Killer cells was also recorded. Cells that were eYFP+ and negative for both 
T cell receptors as well as NK1.1 were also measured.  
 
 
Figure 3.14 shows the summarised data from characterisation of the eYFP+ 
lymphocytes in the spleen. From the pie charts (Fig 3.14A), It can be observed that 
the relatively few cells making up the eYFP+ lymphocyte population within the spleen 
were mostly CD4+ T cells and slightly smaller proportion of these were γδ T cells. Very 
Figure 3.13 The gating strategy used to characterise cells found to eYFP+ through Flow 
cytometry. Cells shown here are from mononuclear cells isolated from the small intestine 
lamina propria.  
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few CD8+ T cells, or cells not expressing T cell receptor or NK1.1 (TCR-NK1.1- cells) 
were positive for eYFP. At day 5, a very small population of eYFP+TCR-NK1.1- cells 
were observed, with the number of CD4+ T cells decreasing in this organ from a 
median of 480 cells at day 0 to 156 at day 5. At day 7 of P. c. chabaudi AS infection, 
this population of lymphocytes not expressing T cell receptor or NK1.1 was not 
observed with CD4+ T cells and γδ T cells once again forming the largest proportion 
of eYFP+ lymphocytes. 
 
 
In the liver, the composition of the eYFP cell population was very different from the 
spleen. As shown in figure 3.15 in naïve mice, CD4+ T cells and cells negative for TCR 
Figure 3.14 The Pie charts represent the proportions of each type of lymphocyte found to be 
positive for eYFP in the spleen as well as numbers of these different cell types. Lines represent 
the median level of expression (n=4).  Representative of 1 experiment. 
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and NK1.1 formed the majority of eYFP+ lymphocytes with both cell types showing a 
similar median number of cells. A small population of T cells that were negative for 
both CD4 and CD8 were also found to be positive for eYFP. At day 5, the median 
number of the TCR-NK1.1- cells slightly increased, forming the large majority of eYFP+ 
lymphocytes at this time point. Day 7 of infection saw a more diverse range of eYFP+ 
lymphocytes as small numbers of CD4+ T cells as well as NK cells, γδ T cells, CD4-CD8- 
T cells and TCR-NK1.1- cells were all observed to be eYFP+. At day 10, again CD4+ T 
cells and cells negative for TCR and NK1.1 formed the small number of eYFP positive 
cells found in the liver at this stage of infection.  
 
Figure 3.15 The Pie charts represent the proportions of each type of lymphocyte found to be 
positive for eYFP in the Liver as well as numbers of these different cell types. Lines represent 
the median level of expression (n=3). Representative of 1 experiment. 
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Within the lungs, where a larger but still small population of eYFP+ lymphocytes 
was observed in the naive mice, it was found that this was largely made up of γδ T 
cells as can be seen in Figure 3.16, with a median number of 978 eYFP+ γδ T cells 
being observed. CD4+ T cells, TCR-NK1.1- cells as well as a small proportion of CD4-
CD8- T cells were also found to be eYFP in the lungs of IL-22 fate reporter mice in 
the steady state. At day 5 of P. c. chabaudi infection, where there was a significant 
increase in eYFP+ lymphocytes in the lungs, this increase was found to be due to 
an increase in the total numbers of γδ T cells to a median of 4,427 cells (p=0.0571, 
Mann-Whitney U-test). The pie chart at day 5 also reveals that the proportion of 
eYFP+ that were γδ T cells also increased from 45% at day 0 to 70% at day 5.  As 
shown in figure 3.11, after day 5 the number of eYFP+ lymphocytes decreased to 
levels similar to that seen in the naive mice.  This change in eYFP+ lymphocytes can 
be observed to be associated with changes in this population of γδ T cells. As the 
numbers of these cells decreased after this time point to levels similar to the naive 
mouse (p=0.0571, Mann-Whitney U-test). The proportion of these cells that were 
eYFP+ was also similar to that seen in the naive with CD4+ T cells and TCR- NK1.1- 
cells becoming more represented again at day 7. At this time point CD4-CD8- T cells 
were also observed in a larger proportion as they increased to a median of 839 cells 
at this time point. By day 10, these T cells reduced in number and the large 
proportion of the eYFP+ lymphocytes were made up of cells negative for TCR and 
NK1.1. 
 58 
  
 
Figure 3.16 The Pie charts represent the proportions of each type of lymphocyte found to be 
positive for eYFP in the lungs as well as numbers of these different cell types Lines represent 
the median level of expression (n=3). Representative of 1 experiment. 
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Figure 3.17 The Pie charts represent the proportions of each type of lymphocyte found to be 
positive for eYFP in the small intestine lamina propria as well as numbers of these different 
cell types (n=4). Lines represent the median level of expression. Representative of 1 
experiment. 
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In the lamina propria of the small intestine, it can be observed from the pie charts 
(fig 3.17) that at day 0, most of the eYFP+ lymphocytes, around 50%, were negative 
for the TCR and NK.1.1 markers. CD4+ cells made up the next largest proportion of 
these cells. At day 5, a slight increase in the numbers of TCR-NK1.1- eYFP+ 
lymphocytes was observed and these cells also formed a larger proportion of this 
population. At day 7, the number of these cells negative for TCR and NK1.1 increased 
further to a median of 41,000 cells. Other cell types were also found to be eYFP+ at 
this time point with CD4+ T cells, CD4+CD8+ T cells and NK cells also being 
represented. At day 10, these TCR-NK1.1- lymphocytes had decreased in number but 
still formed the largest proportions of eYFP lymphocytes.  
 In Naïve mice, in the lamina propria of the large intestine (Figure 3.18), the 
TCR-NK1.1- lymphocytes were the large majority of eYFP+ lymphocytes, around 75%, 
with a median of around 6600 cells.  This number of cells did not change significantly 
at day 5 but the TCR-NK1.1- lymphocytes formed a slightly higher share of the eYFP+ 
lymphocytes.   At day 7, although their numbers grew, the TCR-NK1.1- levels formed 
a slightly lower proportion as the NK cells were also observed to increase in 
frequency. Finally at day 10, the distribution of different lymphocytes resembled that 
in day 0, with the numbers of NK and TCR-NK1.1- cells that were positive for eYFP 
falling. 
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Figure 3.18 The Pie charts represent the proportions of each type of lymphocyte found to be 
positive for eYFP in the large intestine lamina propria as well as numbers of these different cell 
types Lines represent the median level of expression (n=4). Representative of 1 experiment. 
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3.5 Summary of results chapter 1 
In analysing il22 mRNA the spleen, there were no significant changes were observed 
in the median and only very small percentages and numbers of eYFP+ lymphocytes 
observed, strongly suggesting that IL-22 was not produced in this organ during P. c. 
chabaudi infection.  
 Significant increases were observed in the median number of CD45+ 
lymphocytes in the liver and lung during P. c. chabaudi infection. In the liver, there 
were significant increases in il22 mRNA by day 5 and then subsequent decreases. 
Small levels of eYFP+ lymphocytes were observed in this organ, which decreased after 
day 5 of P. c. chabaudi infection. In the lungs, significant decreases were found after 
day 5 of infection. The IL-22 fate reporter mouse showed significant increases in 
eYFP+ lymphocytes by day 5 which then significantly dropped by the peak of 
infection. This transient change was shown to result from the γδ T cell eYFP+ 
population; it would be interesting to find out the cause of this sudden change in γδ 
T cells, whether it could be, for example, as a result of increased apoptosis during 
infection.  
 Il22 mRNA analysis in the small intestine revealed significant decreases 
between day 0 and 7 of P. c. chabaudi infection. However, in the fate reporter mouse, 
trends for increases were observed at the peak of infection. This discrepancy may 
have been due to the permanent labelling of eYFP in IL-22 producing cells. In the large 
intestine, trends for increases in il22 mRNA were observed which were not significant 
and no significant changes in the median level of eYFP lymphocytes.  Based on these 
changes in expression of this cytokine, the next question was what would be the 
impact of the loss of this IL-22 on the progression of P. c. chabaudi infection, whether 
there would be any consequences on the control of the infection or pathology.   
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4. Results - Analysing the consequences of the lack of IL-22 in 
Plasmodium chabaudi infection 
4.1 The loss of IL-22 results in decreased survival of Plasmodium chabaudi infection 
In order to investigate the role of interleukin-22 in malaria infection, interleukin-22 
knockout (il22-/-) mice on a C57BL/6 background were infected with Plasmodium 
chabaudi and markers of pathology were analysed and compared with the wild type. 
Mice were infected with two strains of Plasmodium chabaudi chabaudi: AS and CB. 
As shown in the survival curves in figure 4.1, il22-/- mice were observed to have a 
decreased survival during this infection as compared to that in the wild-type mice in 
which mortality was not observed as a result of P. chabaudi infection. In P. c. 
chabaudi AS infection, 43% mortality was observed in il22-/- mice between days 9 and 
12 of infection. Just after the peak of parasitaemia, which occurs at day 7 of infection. 
No deaths were observed in the infected wild type mice and this difference was found 
to be significant (p=0.0049, Mantel-cox test). In P. c. chabaudi CB infection, il22-/- mice 
showed 50% mortality between days 9 and 10. Again no deaths were reported in the 
 
Figure 4.1 shows the survival curves of il22-/- and wild type infected with P. c. chabaudi AS 
(n=14) and P. c. chabaudi CB (n=10). (* p<0.05, ** p<0.01, horizontal bars show time points 
between which statistical significance was measured using the Gehan-Breslow-Wilcoxon 
test). Representative of 2 experiments for P. chabaudi. A.S. and 1 experiment for P. 
chabaudi C.B. 
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infected wild-type mice, and this difference was significant (p = 0.0163, Mantel-cox 
test). 
4.2 Analysis of increased pathology in Plasmodium chabaudi chabaudi AS infection 
in il22-/-mice 
 
 
When il22-/- and wild type mice were infected with 105 P. c. chabaudi AS, they 
developed a similar courses of parasitaemia, as shown in figure 4.2A, although the 
levels of recrudescence observed at day 15 in il22+/+ mice was absent in il22-/- mice. 
Although il22-/- mice mostly had a similar development of anaemia to that in wild 
type mice, there was a slower rate of recovery in these mice between days 10 and 15 
(figure 4.2B). In figure 4.2C, it can be seen that just after the peak of infection, at day 
10, il22-/- mice had a significantly greater loss of temperature and a significantly 
Figure 4.2 The development of parasitaemia (A), anaemia (B), hypothermia (C) and cachexia 
(D) in il22-/- and il22+/+ injected with 10,000 red blood cells infected with P. c. chabaudi AS. 
Points show the median with the interquartile range (n=7) (* p<0.05, ** p<0.01, *** p<0.001, 
Statistical significance measured using the Mann-Whitney U-test). Representative of 2 
experiments. 
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greater weight loss at day 9 (figure 4.2D). This shows that despite the reduced survival 
seen in P. c. chabaudi infections when IL-22 is absent, approximately 50% of mice 
were still able to control the infection, but all mice exhibited increased pathology.  
 
The detection of increased levels of the enzymes alanine transaminase (ALT) and 
aspartate transaminase (AST) in the plasma is common indicator of damage to the 
liver. As can be observed in figure 4.3, plasma levels of these enzymes were similarly 
low in both groups of naïve mice. However during the infection, levels of these 
enzymes increase and the increase is greater in the il22-/- mice. Levels of ALT were 
significantly greater in il22-/- mice than the wild type at day 7 of P. c. chabaudi AS 
infection (p=0.02) and levels of AST were significantly greater at day 9 (p=0.01).  
 Levels of the liver enzymes alanine transaminase (ALT) and aspartate 
transaminase (AST) were also measured in mice infected with P. c. chabaudi CB at 
day 7 and 9 of infection and whilst naive. As can be observed in figure 4.4, at day 7, 
there is a trend for higher levels of the liver enzymes in il22-/- mice. At day 9 of 
infection the median concentration of both enzymes in the plasma can be observed 
to be significantly higher than in infections of the wild type animals. Surprisingly, the 
Figure 4.3 The levels of liver enzymes in il22-/- and il22+/+ at day 0, 7 and 9 of P. c. chabaudi 
AS infection (n=14) (* p<0.05, horizontal bars show time points between which statistical 
significance was measured using the Mann-Whitney U-test). Box and whisker plots show 
the median with the interquartile range. Representative of 2 experiments. 
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levels of these liver enzymes measured in the wild type at these time points was 
lower than those observed in P. c. chabaudi AS infection. 
Since this increase in liver enzymes suggested a significantly greater level of damage 
to the liver during P. c. chabaudi infection as a result of a lack of IL-22, the 
histopathological changes in this organ were then examined. As can be observed in 
figure 4.5, whilst naive both il22-/- and il22+/+ show no obvious histopathological 
differences whereas at day 9 post-infection it can be observed that in both groups of 
mice, there is damage to the livers associated with this infection. Focal necrosis can 
be observed, (brighter pink areas of the images) as well as increased kupffer cells 
(stained brown). The combined histopathological scores which take into account the 
level of focal necrosis and amounts of Kupffer cells as well as other inflammatory cells 
revealed that, despite the differences observed in levels of liver enzymes, these 
histopathological changes observed in the liver due to P. c. chabaudi infection 
showed no difference based on the loss of IL-22.  
Figure 4.4 Levels of the liver enzymes; alanine transaminase (ALT) and aspartate transaminase 
(AST) detected in the plasma during P. c. chabaudi CB infection. Box and whisker plots show the 
median with the interquartile range. Analysed using Mann-Whitney U-test (n=10) (* p<0.05, ** 
p<0.01, *** p<0.001. Horizontal bars show time points between which significance was measured). 
Representative of 2 experiments.  
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Levels of lactate were also measured in the plasma of mice infected with P. c. 
chabaudi CB as a marker or possible metabolic acidosis. As can be observed in figure 
4.6, the concentration of lactate was similarly low in both il22-/- and wild type mice 
whilst naive. However at day 9 of infection, lactate levels were significantly elevated 
in both groups of mice (wild type mice vs. naïve p=0.0012), with the levels observed 
in the il22-/- group being even more highly elevated than the wild type (p=0.039) 
 
 
Figure 4.5 Histology of the liver in il22-/- and wild type mice whilst naive and at day 9 of P. c. 
chabaudi AS infection. Combined histopathological scores of the livers over a time course of 
P. c. chabaudi infection. Bars show the median with the interquartile range (ns= not statistically 
significant. Statistical significance measured using the Mann-Whitney U-test (n =5). 
Representative of 1 experiment. 
Figure 4.6 Lactate levels in the plasma 
whilst naive and at day 9 of P. c. chabaudi 
CB infection in il22-/- and wild type mice. 
Box and whisker plots represent the 
median and interquartile range. (n=10) (* 
p<0.05, ** p<0.01, horizontal bars show 
time points between which significance 
was measured by the Mann-Whitney U-
test). Representative of 1 experiment. 
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IL-22 is known to also have important protective roles in the lungs and this organ is 
known to be vulnerable to damage during P. c. chabaudi infection (191). 
Histopathological analysis of this organ showed that there was an increase in alveolar 
septae cellularity after the peak of P. c. chabaudi infection as previously shown by 
Brugat et al.  (32). This was not observed to occur at a significantly different level in 
the absence of functional IL-22 (figure 4.7).   
Since no histopathological 
changes were observed in the 
lung as a result of the loss of 
IL-22, measurements of the 
contents of the 
broncheoalveolar lavage 
(BAL) fluid were performed to 
determine whether the 
integrity of the epithelia in this 
organ had been impaired.  This was done by perfusing PBS through the tracheae of 
these mice and then retrieving it. Levels of total protein within this fluid was 
measured by the Bradford assay and quantities of IgM antibodies, were also detected 
by ELISA.  
 The results of this analysis are shown in figure 4.8. The median concentration 
of total protein in the BAL fluid was not significantly different in the il22-/- and il22+/+ 
mice. Although the levels of total protein did not appear to change significantly in 
infection, at day 9, there was a trend for higher total protein in the il22-/- than the 
wild type (p=0.1296). Measurements of total IgM levels in the BAL fluid found 
similarly low concentrations in naive il22-/- and wild type mice. At day 9 of infection, 
Figure 4.7 Histology of the lung of il22-/- and il22+/+ mice 
whilst naive and at day 9 of P. c. chabaudi AS infection. 
Representative of 1 experiment. 
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levels of this protein had risen in both groups of mice, with a trend for higher total 
IgM in the BAL fluid of il22-/- mice (p=0.2747).  
 
IL-22 is known to have active roles in the intestine (115, 118). It has also been 
suggested that this organ may be affected by malaria infection (43, 44). In chapter 3 
(Figure 3.5), levels of this cytokine's mRNA were observed to decrease in the small 
intestine. The intestine was also investigated for histopathological changes in 
Plasmodium chabaudi infection. Sections of the ileal tissue were examined for 
histopathological changes such as blunting of the villi, epithelial loss and neutrophil 
infiltration. As can be observed in images of sections of the ileum stained with 
haematoxylin & eosin (H&E) in figure 4.9A, there were no differences observed due 
to P. c. chabaudi AS infection or due to the lack of IL-22. As previous studies by Turner 
et al.  (159) demonstrated a role for this cytokine in mediating goblet cell hyperplasia 
in helminthic infection, sections were also stained with Alcian Blue period-acid-schiff 
(AB-PAS) which exposes goblet cells as purple dots.  However, counting these cells in 
20 villi crypt units found there were no significant changes in numbers, due to P. c. 
chabaudi AS infection or due to the lack of IL-22 (Figure 4.10). 
Figure 4.8 Total protein concentration and IgM concentration in the BAL fluid whilst naive and at 
day 9 of P. c. chabaudi AS infection in il22-/- and wild type mice. Bars express median level of 
expression. (n=8) (Horizontal bars show time points between which significance was measured 
using the Mann-Whitney U-test). Representative of 1 experiment. 
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Figure 4.9 Sections of the ileum of il22-/- and wild type mice stained with H&E (A) and AB-PAS (B), 
goblet cells staining as purple dots, whilst naive and at day 9 of P. c. chabaudi AS infection. 
Representative of 1 experiment. 
Figure 4.10 Goblet cell counts from 20 villi crypt 
units in the ileum of il22-/- and wild type mice 
whilst naive and at day 9 of P. c. chabaudi AS 
infection. Bars show median with interquartile 
range (horizontal bars show time points 
between which significance was measured 
using the Mann-Whitney U-test) ns = not 
statistically significant (n=5). Representative of 
1 experiment. 
A 
H&E staining in the ileum 
Magnification 4x 
B 
AB-PAS staining in the ileum 
Magnification 4x 
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4.3 Analysing pathology in mosquito transmitted Plasmodium chabaudi chabaudi 
AS  
 
Il22-/- and wild type mice were also infected with Plasmodium chabaudi chabaudi AS 
via 20 mosquito bites using a protocol optimised by Spence et al.  (64). As observed 
in figure 4.11, this mode of transmission resulted in an infection of reduced virulence 
in the wild type as well as il22-/-, as both had a reduced parasitaemia compared to 
when infections were initiated via injection of infected red blood cells. Interestingly, 
at the peak of infection, which occurred at day 10, there was a trend for reduced 
parasitaemia in the infected il22-/- mice (p=0.093). Despite this reduced parasitaemia, 
both il22-/- and wild type mice suffered similar levels of anaemia during this infection.  
 
 
When P. c. chabaudi AS is transmitted through the mosquito in il22-/- reduced survival 
is not observed. However, as shown in figure 4.12, at the peak of infection at day 10, 
infected il22-/- mice can still be observed to have significantly higher levels of ALT in 
this infection even in this less virulent infection.  
Figure 4.11 The resulting parasitaemia and anaemia after il22-/- and wild type mice are infected 
with P. c. chabaudi AS via 20 mosquito bites. Points and bars represent median with the 
interquartile range (n=15). Statistical significance measured using the Mann-Whitney U-test. ns 
= not statistically significant. Representative of 1 experiment. 
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Figure 4.12 Alanine transaminase levels in the plasma 
whilst naive and at day 10 of mosquito transmitted P. c. 
chabaudi AS infection in il22-/- and wild type mice. Box 
and whisker plots represent the median and 
interquartile range. (n=15) (** p<0.01, horizontal bars 
show time points between which significance was 
measured by the Mann-Whitney U-test). Representative 
of 1 experiment. 
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4.5 Summary of Results Chapter 2  
In P. c. chabaudi AS infection in il22-/- mice, a 43% mortality was observed with no 
mortality observed in the wild type. Although there was no difference in parasitaemia 
or anaemia in P. c. chabaudi infection compared to the wild type, due to the loss of 
IL-22, a significant loss of temperature and weight was observed. Furthermore, 
analysis of liver enzymes in the plasma found significant increases in ALT and AST. 
This was also observed in P. c. chabaudi CB infection, however, no significant 
difference in liver histopathology.  No differences in the histopathology of the lungs 
was observed either, although a trend for increased IgM was observed in the 
broncheoalveolar lavage fluid of infected il22-/- mice suggesting the loss of IL-22 may 
have resulted in increased epithelial leakage in this organ. In the intestine there was 
also no discernible difference in histopathology due to P. c. chabaudi AS infection or 
due to the loss of IL-22. However only the gross histopathology of this organ was 
measured. 
 Mosquito transmission of P. c. chabaudi AS resulted in a trend for lower 
parasitaemia in infected il22-/- mice. Despite this, mice that lacked IL-22 still had an 
increased level of ALT in the plasma, suggesting that there was still liver damage 
despite the reduced virulence in this infection.   
 Results from these experiments suggest that IL-22 may have a protective role 
in P. c. chabaudi infection, with the lack of this cytokine resulting in the liver being 
more damaged and the lung epithelial integrity being reduced.  
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5. Discussion  
 
Unlike most cytokines, interleukin-22 does not target other immune cells. It rather 
targets non-haematopoietic cells such as the epithelial cells of the lungs, intestine 
and skin, as well as hepatocytes in the liver. In these organs, as well as others such as 
the pancreas and skin it mediates its functions, which can be protective or pathogenic 
dependent on the context.  
 The aim of this thesis was to investigate the production and role of 
interleukin-22 in the Plasmodium chabaudi mouse model of malaria infection. To 
pursue this, the expression of this cytokine was analysed during infection in the 
spleen, liver as well as the lungs in addition to the small and large intestine. Through 
the use of qRT-PCR, the production of il22 mRNA was analysed, and the production 
as well as characterisation of the cellular sources of this cytokine was performed with 
the use of an IL-22 fate reporter mouse. Another important question to ask was what 
the consequences of the lack of IL-22 in P. c. chabaudi infection were. This was 
addressed with experiments analysing pathology in il22-/- mice infected with 
Plasmodium chabaudi.  
 Since the spleen is a lymphoid organ known to have important roles in malaria 
infection (190), the expression of IL-22 was studied in this organ. Here, mRNA analysis 
found no significant changes in the median during P. c. chabaudi AS infection, 
although there was an early trend towards an increase, as was observed by Mastelic 
et al.  (112). Studies examining eYFP+ cells in the fate reporter mice during this 
infection found very few lymphocytes positive for eYFP whilst naive and this did not 
change in infection.  In combination, this strongly suggests that the spleen is not 
important in secreting IL-22 during P. c. chabaudi infection. Studies in the rat have 
found the spleen to be a site where IL-22 binding protein (IL-22BP) is highly expressed 
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by conventional dendritic cells (145). In these experiments, the spleen was the only 
site where a significant change in median IL-22BP mRNA expression was observed. It 
would be interesting to observe if this could play a role in P. chabaudi infection.    
 There was a significant increase in the number of CD45+ lymphocytes in the 
liver and lung during P. c. chabaudi infection. This agrees with previous studies, which 
have shown that recruitment of immune cells accompanies sequestration of the 
malaria parasite, in these organs, and is associated with in immunopathology (32).  
 In the liver, IL-22 mRNA was found to have increased significantly by day 5 of 
P. c. chabaudi infection and then subsequently decreased significantly by day 7. This 
pattern of expression is similar to that observed in previous experiments reported by 
Mastelic et al.  (112). In the fate reporter mouse this decrease could also be observed 
by day 7 of infection in the percentages of eYFP+ lymphocytes, however it was not 
reflected in the cell numbers. This could be explained by the expansion of 
lymphocytes other than those that are eYFP+ at the peak of infection, since as 
aforementioned, total numbers of CD45+ lymphocytes are observed to increase 
significantly in this infection.   
 Intracellular cytokine staining was attempted for this cytokine in lymphocytes 
isolated from the liver, however the IL-22 fate reporter mouse was resorted to as an 
alternative since only very low numbers of lymphocytes could be found to be positive 
for IL-22 in the naive mouse. Analysis of data produced from flow cytometry using 
this mouse demonstrate that these issues with intracellular cytokine staining 
stemmed from the fact that IL-22 is not produced in large amounts in the liver, 
despite the important role of this cytokine in protection from liver damage, due to 
injury or to infection (153, 154).  
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 Mastelic et al.  (112) found that CD8+ T cells were the largest producers of IL-
22 in P. c. chabaudi infection. These cells have been shown to produce IL-22 in other 
circumstances as well (136). However studies with the fate reporter mouse did not 
find significant production of this cytokine by this cell type. Rather, CD4+ T cells were 
shown here to be much larger producers of IL-22. It is unlikely that this discrepancy 
was caused by the different techniques used to assay for cellular production of IL-22.  
 The lungs were also found to have a decrease in il22 mRNA expression after 
day 5 of P. c. chabaudi infection.  In the percentages and numbers of eYFP+ 
lymphocytes there was a strikingly similar result of an increase at day 5 of the 
infection and a subsequent decrease back to original levels. This change in the 
median was significant. Characterising these cells revealed that this was due to 
changes in the size of the eYFP+ γδ+ T cell population.  Although the decreases were 
back to levels observed in the naive mouse, the fact that this decrease occurs at the 
peak of infection where there is a greater risk of inflammatory damage may mean 
that the protective effects of IL-22 in the lung seen in other infection models (137, 
172, 192) are lost when epithelial cells are most vulnerable. It is possible that this 
may contribute to the pathology associated with sequestration seen in the lung at 
the peak of P. c. chabaudi AS infection in C57BL/6 as described by Brugat et al.  (32).   
 For the small intestine, mRNA analysis found a significant decrease in il22 
during the time course of P. c. chabaudi infection, however no significant changes 
were observed in the median percentages of eYFP+ lymphocytes. The numbers of 
eYFP+ lymphocytes rather showed a trend for increase at day 7 of P. c. chabaudi 
infection. This discrepancy may be explained by the fact that the fate reporter mouse 
permanently labels IL-22 producing cells as eYFP+, recording cumulative expression 
over time, thus these eYFP positive cells may not necessarily be actively producing 
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this cytokine at this time. Further work could investigate this by employing the use of 
intracellular cytokine staining with the fate reporter mouse to confirm the production 
of IL-22 protein in these cells. In the large intestine, significant changes in il22 mRNA 
expression were not observed. There was a trend, however, for increased expression 
till day 5 of P. c. chabaudi infection. There was also no significant difference in the 
percentages of eYFP+ lymphocytes during this infection. In a lot of these analyses of 
eYFP total numbers and percentages statistical significance was not observed in 
differences. In future work it would be important to repeat these experiments with 
larger groups of mice for statistical power.   
 Of the cells that were eYFP+ in the small intestine whilst naive and during 
infection, a large majority were shown to be CD45+ and negative for T-cell or NK cell 
markers. There is a strong likelihood that these are innate lymphoid cells, as this 
population was also found to conform to the large majority of this organ's eYFP+ 
lymphocytes in the work of Ahlfors et al.  (186). As reviewed by Spits et al.  (193), 
innate lymphoid cells are important sources of cytokines that lack antigen receptors. 
As markers that are unique to innate lymphoid cells have not yet been identified, 
further analysis would require the use of a "dump channel" which contains markers 
for T, B and NK cells such as CD3, CD19 and DX5 in order to ensure that eYFP+ cells 
analysed are correctly identified as innate lymphoid cells (194). Developments in 
Flow cytometry technology allowing analysis of more than 12 parameters in the same 
experiment make this now feasible (195, 196).  
 Ahlfors et al.  (186), commented on the lower than expected eYFP+ 
populations being observed in the IL-22 fate reporter mouse, since the expression of 
both eYFP+ and IL-22 was observed to be low as compared to studies done in the IL-
17 fate reporter mouse (188). It was suggested that this may be due to the expression 
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of IL-22 being monoallelic like has been shown for IL-10 (197). Since, in the fate 
reporter mouse, one allele of IL-22 is disabled by the introduction of cre recombinase, 
the possibility of IL-22 expression being monoallelic would lead to reduced eYFP+ 
cells being observed.  
 The cytokine, interleukin-12 has been shown to be important for stimulating 
protective immune response in P. c. chabaudi AS infection (55). This cytokine has also 
been shown to be able to induce plasticity in group 3 innate lymphoid cells, 
stimulating production of IFN-γ by these cells, rather than IL-22 (198). It would be 
interesting to observe whether eYFP+ innate lymphoid cells observed in the intestine 
lamina propria switch to producing IFN-γ as a result of increased systemic levels of IL-
12 in P. c. chabaudi infection. This may explain observations of decreased il22 mRNA 
in the studies detailed here in the small intestine lamina propria. As the IL-22 fate 
reporter mouse has all cells that have produced IL-22 permanently labelled with 
eYFP, cells that may have switched to expressing IFN-γ would have been included in 
analysis. This could be further investigated through the use of intracellular cytokine 
staining for both IL-22 and IFN-γ in lymphocytes isolated from the P. c. chabaudi 
infected IL-22 fate reporter mouse. By comparing the fractions of eYFP+ cells that are 
positive for IL-22 or IFN-γ at various time points in the acute infection, possible 
switching of cytokine production in these cells may become apparent.   
 In this study, the role of interleukin-22 in P. c. chabaudi infection was also 
investigated by examining the consequences on the development of the infection as 
well as the pathology in the absence of this cytokine. To do this, il22-/- mice were 
infected with P. c. chabaudi AS or P. c. chabaudi CB via injection of infected red blood 
cells. Il22-/- mice were also infected with P. c. chabaudi AS via mosquito bite.  
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 In P. c. chabaudi AS infection, il22-/- mice were observed to have a decreased 
survival despite having similar levels of parasitaemia as the infected wild type mice. 
This strongly suggests a decreased tolerance of the pathology of infection as 
discussed by Ayres & Schneider (199). Weight and temperature loss were also 
significantly greater due to the loss of IL-22, around the peak of P. c. chabaudi 
infection. P. c. chabaudi CB also caused significant weight and temperature loss in 
infected il22-/- mice. Although, no significant difference was observed when 
compared to the wild type in infection, possibly because of the increased severity of 
this infection. 
 On infection with P. c. chabaudi AS through the injection of infected red blood 
cells, no differences were observed in parasitaemia due to the loss of IL-22. However, 
in a mosquito transmitted P. c. chabaudi AS infection, a trend for a lower peak of 
parasitaemia was observed in infected il22-/- mice. This infection differed from the 
direct injection of infected red blood cells in that the mosquito-bite transmitted 
sporozoites into the skin of the mice, which developed into merozoites within the 
liver. Although there are still increases in liver enzymes in this model of malaria 
infection and infected il22-/- mice still had a significantly higher level than the wild 
type. It may be interesting to investigate whether the liver, without IL-22, may 
provide a more difficult environment for sporozoites to grow possibly from the lack 
of survival factors that IL-22 induces in the liver in il22-/- mice (157) resulting in 
hepatocytes in these mice being less able to support the parasitic infection. However, 
the initial blood stage parasitaemia soon after egress from the liver in in il22-/- mice 
was be similar to the wild type, suggesting that the same number of merozoites may 
have emerged from the liver. This could be further investigated by measuring the 
magnitude of 18s RNA from sporozoites by qRT-PCR in the liver 42 hours after 
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mosquito bite as has been done by Nahrendorf et al.  (200). Doing this in il22-/- mice 
as well as the wild type could show whether differences in the liver due to the loss of 
IL-22 affect the growth of sporozoites in the liver stage and whether this results in 
the differences observed in the parasitaemia of il22-/- mice. 
 In these investigations of the role of interleukin-22 in P. c. chabaudi, the 
possibility of this cytokine playing a role in the skin was not investigated. IL-22 has 
been shown to have important roles in the skin, the most documented case being 
psoriasis (201). Work in the naive IL-22 fate reporter mouse has shown the majority 
of eYFP+ cells in the skin were γδ+ T cells (186). Immune changes have been described 
in this organ during malaria infection but the possibility of a role of IL-22 here has not 
been investigated. This could be done by analysing changes in eYFP+ cells in fate 
reporter mice shortly after transmission of P. c. chabaudi AS via mosquito bite using 
the protocol of Spence et al.  (64). Doing this analysis in both wild type and il22-/- mice 
could reveal whether the lack of IL-22 could reveal whether this cytokine could affect 
number of sporozoites reaching the liver by analysing the liver burden as well in these 
mice.   
 Analysis of liver enzymes in the plasma revealed that infected il22-/- mice had 
significantly higher levels than the wild type mice in both P. c. chabaudi AS and P. c. 
chabaudi CB infections. Interestingly, this was also observed in mosquito transmitted 
P. c. chabaudi AS infection even though there was a reduced level of virulence with 
no mortality being observed in infected il22-/- mice. However, no discernible 
differences were observed in the histopathology of the liver in P. c. chabaudi AS 
infection due to the loss of IL-22. This may mean that the difference in liver damage 
shown in ALT measurements between infected il22-/- mice and the infected wild type 
mice may be too subtle to be observed through histopathology since considerable 
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liver damage is a common feature for P. c. chabaudi AS infection. This strongly 
suggests that liver damage may not be the main cause of the loss of survival in 
infected il22-/- mice.  
 In studies of the lung during P. c. chabaudi AS infection, Brugat et al.  (32) 
found an increased infiltration of IFN-γ producing lymphocytes as well as increased 
IgM in the broncheoalveolar lavage fluid, an indicator of epithelial damage leading to 
decreased integrity. In the experiments detailed here, IgM was found to increase in 
both infected il22-/- mice and, as expected, the wild type mice during infection. A 
trend was found for higher IgM in the infected il22-/- mice, with a higher median level 
found here. This suggests that the loss of IL-22 may slightly compromise the epithelial 
integrity within the lung further. However, experiments to analyse the total protein 
level in the BAL found no significant differences due to the infection. Although, 
infected il22-/- mice did again show a trend for higher protein levels in the BAL than 
the wild type. As with the liver, no obvious differences were observed in the 
histopathology of P. c. chabaudi AS infection due to the loss of IL-22, increased 
alveolar septae cellularity was observed to a similar degree. This may suggest in both 
these organs changes due to the loss of IL-22 in this model of malaria infection may 
only be very subtle. Il22 mRNA analysis as well as studies in the fate reporter mouse 
showed decreases in IL-22 expression at the peak of P. c. chabaudi infection that were 
mediated by changes in the γδ+ T cell population.  
 In examination of the histopathology within the intestine, no changes were 
observed due to the loss of IL-22 or P. c. chabaudi AS infection. It was hypothesised 
that this cytokine may protect the epithelia of this organ and thus its loss may result 
in damage to the epithelia. Sections of this organ were examined with H&E as well as 
AB-PAS staining which showed little differences or change in goblet cell numbers. In 
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experiments by Chau et al.  (43), intestine epithelial integrity during Plasmodium 
yoellii infection was examined by immunofluorescence staining of tight junction 
proteins. Using this technique could signal changes in malaria infection that could be 
influenced by the lack of IL-22.  
 Clearly, an important role for IL-22 in the intestine is its influence on the 
microbiota through regulating levels of antimicrobial peptides (202-204) and 
glycosylation of the epithelia (164, 165).  IL-22 has a role in maintaining the integrity 
of the intestine epithelia preventing dissemination of bacteria. Work by Aujla et al.  
(174) found this cytokine was able to induce the antimicrobial peptides β-defensin 2 
and β-defensin 3 to protect against the pathogen Klebsiella pneumoniae in the lung. 
This cytokine also induces RegIIIβ and RegIIIγ providing an innate immune response 
against Citrobacter rodentium infection in the intestine (205). In further work, it 
would be of interest to investigate whether the loss of IL-22 an important inducer of 
these antimicrobial peptides in the steady state, could result in decreased epithelial 
integrity and how this could explain increased pathology observed in P. c. chabaudi 
infected il22-/- mice. Antimicrobial peptides are unlikely to directly inhibit growth of 
malaria parasites, however, decreased production of antimicrobial peptides in the 
loss of IL-22 in P. c. chabaudi infection could result in decreased integrity of the gut 
epithelial barrier leading to the dissemination of bacteria or their products. Studies 
by Sonnenberg et al. (204) demonstrated the ability of this cytokine in protecting the 
epithelial integrity of the intestine by showing greater dissemination of intestinal 
bacteria to the spleen and liver in C57BL/6 RAG-/- mice who had their IL-22 producing 
ILCs depleted using an antibody against CD90.2.  
 Sequestration of P. c. chabaudi has been shown to occur in the intestine, 
although lower than at other sites such as the liver and lung. This was done through 
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imaging organs of mice infected with genetically engineered fluorescent parasites 
expressing the enzyme luciferase (32). This may well be associated with changes in 
immune and inflammatory cell populations, which could threaten the integrity of the 
epithelia.   
 Freudenberg et al.  (40) showed that the lethal dose of LPS was lower in mice 
infected with P. c. chabaudi, strongly suggesting that malaria infection may prime 
responses. This has been recently supported by evidence showing that P. c. chabaudi 
AS infection can lead to excessive amounts of the proinflammatory cytokine, IL-1β 
being secreted leading to inflammatory damage (41).    
 This hypothesis of bacterial or endotoxin dissemination could explain 
observations made in measurements of liver enzymes in the plasma. Work by Balmer 
et al.  (206) indicated that the liver can act as a firewall to clear commensal bacteria 
which disseminate from the intestine into the bloodstream. If increased 
dissemination of bacteria occurs in malaria infection, increased levels of LPS could 
induce further liver injury and further increases in ALT and AST. However if this was 
the case, it could be argued that the ensuing increased inflammatory response in il22-
/- mice to LPS in P. c. chabaudi infection would be more clearly observed as a 
difference from the wild type e.g. induction of pulmonary oedema, a feature that 
increased endotoxaemia has been shown to induce, was not observed in these 
studies such as in histopathology of the lung (207).   
 Increased endotoxaemia as well as bacterial coinfections are known to be a 
feature of malaria infection (36, 37), it would be interesting to investigate further 
whether IL-22 may act to mitigate this. This phenomenon may, in part, explain 
variability observed in some results between experiments such as mortality. Mice in 
these experiments were housed in a specific pathogen free unit, which would surely 
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influence the gut microbiota, and possible bacterial or LPS translocation may vary 
due to this. Future investigations would need to take this into account; this could be 
done by analysing differences that could occur in the microbiota in P. c. chabaudi as 
well as on the loss of IL-22. Behnsen et al. have conducted studies such as this (208), 
where 16s rRNA sequencing was used to analyse the representation of different 
populations of bacteria within the microbiota.  By using this technique, a key 
experiment could be done to answer whether changes in the microbiota within the 
intestine due to the loss of IL-22 make C57BL/6 more vulnerable to P. chabaudi AS 
infection.  Experiments using "cohousing" of mice could also be performed to answer 
this question. This has been done in studies such as those by Zenewicz et al.  (163) 
where they housed wild type mice with il22-/- mice in the same cages for 4-6 weeks 
when the altered microbiota of the il22-/- mice was transmitted to the wild type mice. 
After this, they induced colitis using dextran sodium sulfate (DSS) and found that wild 
type mice with microbiota similar to il22-/- mice exhibited the exacerbated pathology 
in DSS induced colitis usually associated with il22-/- mice. By cohousing il22-/- and 
wild type mice and then infecting them with P. c. chabaudi AS it would be possible to 
ask the question of whether the difference in microbiota in il22-/- mice could play a 
role in enhanced pathology when these mice are infected. 
 The mouse model of malaria infection, Plasmodium chabaudi, has important 
uses due to the similarities it shares with the most dangerous malaria parasite 
infecting humans, Plasmodium falciparum (54). This model of malaria infection was 
useful here in studying the role of IL-22 as it normally causes a low level of pathology 
in wild type mice. This allowed the possibility of clear differences in pathology of mice 
lacking IL-22 to be observed. Another species of malaria parasite that could be used 
to study pathology in malaria infection due to the lack of IL-22 through a mouse 
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model include Plasmodium berghei. Deroost et al have used the parasite, 
Plasmodium berghei NK65 to study lung pathology (191) and found a significantly 
higher level of protein in the BAL fluid in infection than with P. c. chabaudi AS. The 
protective role of IL-22 may be more easily observed in a malaria infection where 
there is a greater scale of pathology than P. chabaudi.  
 Koch et al.  (114) identified two single nucleotide polymorphisms in the IL22 
gene that showed a weak association with resistance and susceptibility to severe 
malaria in West African children. In these studies, severe malaria was defined by the 
presence of cerebral malaria or severe anaemia. However, experiments detailed 
within this thesis did not find signs of these complications in P. c. chabaudi AS 
infected il22-/- mice. In further work, it would be of interest to investigate whether 
polymorphisms of the il22 gene are associated with the increased endotoxaemia (36) 
as well as bacteraemia (37, 210) observed in malaria infected humans. Levels of LPS 
in the plasma, a marker of dissemination could be studied using the limulus 
amoebocyte assay as has been done in studies of microbial translocation from the 
intestine in SIV infected macaques (211). In these studies, the histopathology 
associated with microbial translocation was not examined.   
 If IL-22 does indeed have a protective role in malaria infection, the 
therapeutic opportunities of this cytokine, as reviewed by Sabat et al.  (121) could be 
harnessed in the future for use in the field to treat patients found to be at greater 
risk of suffering from severe malaria. It is possible that individuals with mutations in 
this cytokine could be suffering from increased severity in malaria due to reduced 
integrity of the epithelia and lung. This could allow dissemination of bacteria or their 
products, therefore exacerbating an already increased inflammatory state.  
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6. Conclusions  
 
This aim of this thesis was to investigate the production of interleukin-22 and the 
consequences of its lack, in the mouse model of malaria, Plasmodium chabaudi. This 
was examined by analysing the expression of this cytokine’s mRNA as well as its 
cellular production during this infection. The pathological consequences that ensued 
when this cytokine was absent in Plasmodium chabaudi were also examined.  
 The spleen was concluded to not be an important site of IL-22 production in 
this infection. In the liver and lung, there were transient increases in il22 mRNA. In 
the lung this was due to changes in the population of γδ T cells. The intestine, where 
IL-22 is expressed in the largest amounts, showed significant decreases in this 
cytokine's mRNA in the small intestine and no significant changes in the large 
intestine. A significant increase was observed in eYFP+ cell numbers in the small 
intestine lamina propria but no changes were observed in the large intestine. Further 
work would need to investigate the proportion of eYFP+ cells that switch to producing 
IFN-γ in P. c. chabaudi infection compared to those that remain IL-22 producers. 
 The stark mortality observed in P. c. chabaudi AS and P. c. chabaudi CB 
infected il22-/- mice strongly suggested that this cytokine plays an important role in 
malaria infection. This was associated in increased liver enzymes and lactate in the 
plasma. A trend for increased IgM in the BAL fluid of infected il22-/- mice strongly 
implied an enhanced reduction of epithelial integrity in P. c. chabaudi infection on 
the loss of IL-22. Histopathological changes were observed in infection due to the loss 
of IL-22 in the liver, lungs or the ileum. Later experiments encountered issues with 
reproducibility, showing that the role IL-22 might be subtler than previously 
envisaged.   
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 To conclude the lungs and the intestine may be vulnerable to damage from 
an increased inflammatory state due to P. c. chabaudi infection. IL-22 may well have 
an important role in protecting these epithelia and preventing dissemination of 
bacterial products, further work will need to study this subtle action of this cytokine 
by analysing the epithelial integrity in the intestine such as by analysing antimicrobial 
peptide production and levels of LPS in the plasma. 
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